UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 30, 2015

 


 

GLAUKOS CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-37463

 

33-0945406

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

26051 Merit Circle, Suite 103
Laguna Hills, California

 

95263

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (949) 367-9600

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

o                  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 1.01 Entry Into a Material Definitive Agreement.

 

On June 30, 2015, pursuant to the terms of an Asset Purchase Agreement, dated as of July 10, 2014, between Glaukos Corporation and DOSE Medical Corporation, or DOSE, we completed the purchase from DOSE of certain glaucoma-related patents, pending patents, trademarks and related rights and tangible assets for consideration consisting of $15,000,000 cash and the cancellation of all indebtedness of DOSE to us as of June 30, 2015.  The amount of the indebtedness cancelled was approximately $10.9 million. We determined the valuation for the assets of DOSE based in part on the results of a valuation conducted by an independent third-party. Our stockholders and the stockholders of DOSE approved the terms of the asset purchase.

 

Prior to the closing of the asset purchase from DOSE, our president and chief executive officer, Thomas W. Burns, served as president and chief executive officer of DOSE, and Richard L. Harrison, our treasurer, chief financial officer and secretary, served as the chief financial officer and secretary of DOSE.  Messrs. Burns and Harrison each resigned as an officer of DOSE effective as of the closing of the asset sale to us. Two of our current directors, Mr. Burns and William J. Link, served as the members of the board of directors of DOSE prior to the closing and continue to serve in that capacity.

 

On June 30, 2015, concurrent with our purchase of the glaucoma-related assets for DOSE, we entered into an amended and restated patent license agreement and an amended and restated transition services agreement with DOSE.

 

Under the terms of the amended and restated patent license agreement, we received a worldwide exclusive license to practice certain of DOSE’s existing patents and future related patents in connection with applications for the treatment of glaucoma or any disorder or disease primarily affecting the anterior segment of the eye. We also received the right to use certain regulatory data and submissions of DOSE for our products in our exclusive fields. In return, DOSE received a worldwide exclusive license to practice certain of our existing patents and future related patents in applications involving biosensors and/or in applications for the treatment of any disorder or disease (other than glaucoma) primarily affecting the posterior segment of the eye. DOSE also received the right to use certain of our regulatory data and submissions for its products in its exclusive fields. Each license is fully paid-up, irrevocable, and perpetual, and includes the right to sublicense.

 

Under the terms of the amended and restated transition services agreement, we will continue to provide DOSE with certain accounting, financial, legal, human resource and benefits administrative services, IT support and limited engineering support and such additional services to which the parties may agree for a period of three years for a fee of $4,500 per month. If additional services are provided to DOSE, the monthly fees will be increased appropriately. Additionally, DOSE will pay us rent of $1,500 per month for the use of a portion of space sublet from us by DOSE. If DOSE uses more of the premises subject to the sublease, the monthly rent will be increased appropriately. DOSE may terminate the agreement on 60 days’ notice and Glaukos may terminate the agreement on 180 days’ notice. A copy of the amended and restated patent license agreement and the amended and restated transition services agreement are attached to this Form 8-K as Exhibits 10.1 and 10.2, respectively.

 

2



 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

The disclosure in Item 1.01 is incorporated herein by reference.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Upon completion of our initial public offering of shares of our common stock (the “ IPO ”) on June 30, 2015, and as described in our Registration Statement on Form S-1, as amended (File No. 333-204091), Paul S. Madera and Robert J. More voluntarily resigned from our board of directors and our board was decreased from 11 members to nine members.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On June 30, 2015, we filed a restated certificate of incorporation (the “ Restated Certificate ”) with the Secretary of State of the State of Delaware in connection with the closing of our IPO. As described in our Registration Statement on Form S-1, as amended (File No. 333-204091), our board of directors and stockholders previously approved the Restated Certificate to be effective upon the closing of our IPO.

 

A copy of the Restated Certificate is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

Our adopted amended and restated bylaws (the “ Restated Bylaws ”) became effective as of June 30, 2015, in connection with the closing of our IPO. Our board of directors and stockholders previously approved the Restated Bylaws to be adopted in connection with, and to be effective upon, the closing of our IPO.

 

A copy of the Restated Bylaws is attached hereto as Exhibit 3.2 and is incorporated herein by reference.

 

Item 9.01                                   Financial Statements and Exhibits.

 

(d)          Exhibits

 

Exhibit No.

 

Description

3.1

 

Restated Certificate of Incorporation

 

 

 

3.2

 

Bylaws, as currently in effect

 

 

 

10.1

 

Amended and Restated Patent License Agreement dated as of June 30, 2015 by and between Glaukos Corporation and DOSE Medical Corporation

 

 

 

10.2

 

Amended and Restated Transition Services Agreement dated as of June 30, 2015 by and between Glaukos Corporation and DOSE Medical Corporation

 

3



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

GLAUKOS CORPORATION

 

 

 

 

 

 

 

By:

/s/ RICHARD L. HARRISON

 

 

Name: Richard L. Harrison

 

 

Title: Chief Financial Officer

 

Date: June 30, 2015

 

4


Exhibit 3.1

 

RESTATED

 

CERTIFICATE OF INCORPORATION OF

 

GLAUKOS CORPORATION

 

(originally incorporated July 14, 1998 under the name Transdx, Inc.)

 

ARTICLE I

 

The name of the corporation is Glaukos Corporation (the “ Corporation ”).

 

ARTICLE II

 

The address of the Corporation’s registered office in the State of Delaware is 1201 North Market Street, Post Office Box 1347, City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at such address is Delaware Corporation Organizers, Inc.

 

ARTICLE III

 

The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which corporations may be organized under the Delaware General Corporation Law (“ DGCL ”).

 

ARTICLE IV

 

Section 1.                                            The Corporation is authorized to issue two classes of stock designated “Common Stock” and “Preferred Stock.” The total number of shares of stock that the Corporation shall have authority to issue is One Hundred Fifty-Five Million (155,000,000) shares, of which One Hundred Fifty Million (150,000,000) shares are Common Stock, $0.001 par value, (“ Common Stock ”) and Five Million (5,000,000) shares are Preferred Stock, $0.001 par value, (“ Preferred Stock ”). Except as otherwise provided in any certificate of designations of any series of Preferred Stock, the number of authorized shares of the class of Common Stock may from time to time be increased or decreased (but not below the number of shares of such class outstanding) by the affirmative vote of the holders of a majority of the voting power of the outstanding shares of capital stock of the Corporation irrespective of the provisions of Section 242(b)(2) of the DGCL.

 

Section 2.                                            Common Stock.  Subject to all the rights, powers and preferences of the Preferred Stock and except as provided by law or in this Restated Certificate of Incorporation (or in any certificate of designations of any series of Preferred Stock):

 

(a)  each share of Common Stock shall entitle the holder thereof to one (1) vote on any matter submitted to a vote at a meeting of stockholders;

 

(b)  dividends may be declared and paid or set apart for payment upon the Common Stock out of any assets or funds of the Corporation legally available for the payment of dividends, but only when and as declared by the Board of Directors or any authorized committee thereof; and

 



 

(c)  upon the voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the assets or funds of the Corporation legally available for distribution shall be distributed pro rata to the holders of the Common Stock.

 

Section 3.                                            Preferred Stock.  The Preferred Stock may be issued from time to time in one or more series pursuant to a resolution or resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of Preferred Stock, including, without limitation, authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing. The Board of Directors is further authorized to increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any series, the number of which was fixed by it, subsequent to the issuance of shares of such series then outstanding, subject to the powers, preferences and rights, and the qualifications, limitations and restrictions thereof stated in this Restated Certificate of Incorporation or the resolution of the Board of Directors originally fixing the number of shares of such series. If the number of shares of any series is so decreased, then the Corporation shall take all such steps as are necessary to cause the shares constituting such decrease to resume the status which they had prior to the adoption of the resolution originally fixing the number of shares of such series.

 

Section 4.                                            Except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to this Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock).

 

ARTICLE V

 

Section 1.                                            The business and affairs of the Corporation shall be managed by or under the direction of a Board of Directors.  In addition to the powers and authority expressly conferred upon them by statute or by this Restated Certificate of Incorporation or the Bylaws of the Corporation, the directors are hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation.  The number of directors that constitutes the entire Board of Directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation.

 

2



 

Section 2.                                            At each annual meeting of stockholders, directors of the Corporation shall be elected to hold office until the expiration of the term for which they are elected and until their successors have been duly elected and qualified or until their earlier resignation or removal; except that if any such meeting shall not be so held, such election shall take place at a stockholders’ meeting called and held in accordance with the DGCL and the Bylaws of the Corporation. The election of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.

 

Section 3.                                            From and after the effectiveness of this Restated Certificate of Incorporation, the directors of the Corporation (other than any who may be elected by holders of Preferred Stock under specified circumstances) shall be divided into three classes as nearly equal in size as is practicable, hereby designated Class I, Class II and Class III. Directors already in office shall be assigned to each class at the time such classification becomes effective in accordance with a resolution or resolutions adopted by the Board of Directors. At the first annual meeting of stockholders following the date hereof, the term of office of the Class I directors shall expire and Class I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following the date hereof, the term of office of the Class II directors shall expire and Class II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following the date hereof, the term of office of the Class III directors shall expire and Class III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. If the number of directors is changed, any newly created directorships or decrease in directorships shall be so apportioned among the classes as to make all classes as nearly equal in number as is practicable.  Whenever the holders of one or more classes or series of Preferred Stock shall have the right, voting separately as a class or series, to elect directors, the nomination, election, term of office, filling of vacancies, removal and other features of such directorships shall be governed as set forth in the certificate of designation for such class or series and shall not be governed by this Section 3 of Article V or by Section 4 or Section 5 of this Article V unless otherwise provided for in the certificate of designation for such class or series.

 

Section 4.                                            Any director or the entire Board of Directors may be removed from office at any time, but only for cause, and only by the affirmative vote of the holders of at least seventy-five percent (75%) of the voting power of the outstanding capital stock of the Corporation entitled to vote in the election of directors. At least forty-five (45) days prior to any annual or special meeting of stockholders at which it is proposed that any director be removed from office, written notice of such proposed removal and the alleged grounds thereof shall be sent to the director whose removal will be considered at the meeting.

 

Section 5.                                            Except as otherwise provided for or fixed by or pursuant to the provisions of Article IV hereof in relation to the rights of the holders of Preferred Stock to elect directors under specified circumstances, newly created directorships resulting from any increase in the number of directors, created in accordance with the Bylaws of the Corporation, and any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other cause shall be filled only by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director, and not by the stockholders. A person so elected by the Board of Directors to fill a vacancy or newly created directorship shall hold office until the next election of the class for which such director shall have been chosen until his or her successor shall have been duly elected and qualified, or until such director’s earlier death, resignation or removal.

 

3



 

Section 6.                                            Notwithstanding anything herein to the contrary, no decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.

 

ARTICLE VI

 

Section 1.                                            The Corporation is to have perpetual existence.

 

Section 2.                                            In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to adopt, alter, amend or repeal the Bylaws of the Corporation or any provision thereof. The affirmative vote of at least a majority of the Board of Directors then in office shall be required in order for the Board of Directors to adopt, amend, alter or repeal the Corporation’s Bylaws or any provision thereof. The Corporation’s Bylaws (or any provision thereof) may also be adopted, amended, altered or repealed by the stockholders of the Corporation, by the affirmative vote of at least seventy-five percent (75%) of the then outstanding voting securities of the Corporation entitled to vote on such amendment or repeal, voting together as a single class; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal at a meeting of stockholders, such amendment or repeal shall only require the affirmative vote of the majority of the outstanding voting securities of the Corporation entitled to vote on such amendment or repeal, voting together as a single class. No Bylaw hereafter legally adopted, amended, altered or repealed shall invalidate any prior act of the directors or officers of the Corporation that would have been valid if such Bylaw had not been adopted, amended, altered or repealed.

 

ARTICLE VII

 

Section 1.                                            Subject to the rights of the holders of shares of any series of Preferred Stock or any other class of stock or series thereof that have been expressly granted the right to take action by written consent, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders.

 

Section 2.                                            Special meetings of stockholders of the Corporation may be called only by the Chairperson of the Board of Directors, the Chief Executive Officer, the President or the Board of Directors acting pursuant to a resolution adopted by a majority of the Board of Directors, and any power of stockholders to call a special meeting of stockholders is specifically denied. The Board of Directors may cancel, postpone or reschedule any previously scheduled special meeting at any time, before or after the notice for such meeting has been sent to the stockholders. Only such business shall be considered at a special meeting of stockholders as shall have been stated in the notice for such meeting.

 

Section 3.                                            Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner and to the extent provided in the Bylaws of the Corporation.

 

Section 4.                                            No stockholder will be permitted to cumulate votes at any election of directors.

 

4



 

ARTICLE VIII

 

Section 1.                                            To the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended from time to time, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (a) for any breach of the director’s duty of loyalty to the Corporation or its stockholders, (b) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) under Section 174 of the DGCL or (d) for any transaction from which the director derived an improper personal benefit. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.

 

Section 2.                                            The Corporation shall indemnify, to the fullest extent permitted by applicable law, any director or officer of the Corporation who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “ Proceeding ”) by reason of the fact that he or she is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding. The Corporation shall be required to indemnify a person in connection with a Proceeding initiated by such person only if the Proceeding was authorized by the Board of Directors.

 

Section 3.                                            The Corporation shall have the power to indemnify, to the extent permitted by applicable law, any employee or agent of the Corporation who was or is a party or is threatened to be made a party to any Proceeding by reason of the fact that he or she is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding.

 

Section 4.                                            Neither any amendment nor repeal of any Section of this Article VIII, nor the adoption of any provision of this Restated Certificate of Incorporation or any Bylaws of the Corporation inconsistent with this Article VIII, shall eliminate or reduce the effect of this Article VIII in respect of any matter occurring, or any cause of action, suit, claim or proceeding accruing or arising or that, but for this Article VIII, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.

 

5



 

ARTICLE IX

 

Meetings of stockholders may be held within or outside of the State of Delaware, as the Bylaws may provide. The books of the Corporation may be kept (subject to any provision contained in the DGCL) outside of the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation.

 

ARTICLE X

 

Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (A) any derivative action or proceeding brought on behalf of the Corporation, (B) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation’s stockholders, (C) any action or proceeding asserting a claim arising pursuant to any provision of the DGCL or the Corporation’s Certificate of Incorporation or Bylaws, or (D) any action or proceeding asserting a claim governed by the internal affairs doctrine.

 

ARTICLE XI

 

The Corporation reserves the right to amend or repeal any provision contained in this Restated Certificate of Incorporation in the manner prescribed by the laws of the State of Delaware and all rights conferred upon stockholders are granted subject to this reservation; provided, however , that notwithstanding any other provision of this Restated Certificate of Incorporation or any provision of law that might otherwise permit a lesser vote or no vote, the Board of Directors acting pursuant to a resolution adopted by a majority of the Board of Directors and the affirmative vote of seventy-five percent (75%) of the then outstanding voting securities of the Corporation, voting together as a single class, shall be required for the amendment, repeal or modification of the provisions of Section 3 of Article IV, Sections 3, 4 and 5 of Article V, Article VII, Article VIII, Article XI or this Article XI of this Restated Certificate of Incorporation.

 

ARTICLE XII

 

The Corporation renounces any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity.  An “ Excluded Opportunity ” is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of, (a) any director of the Corporation who is not an employee or consultant of the Corporation or any of its subsidiaries, or (b) any holder of Preferred Stock or any partner, member, director, stockholder, employee or agent of any such holder, other than someone who is an employee or consultant of the Corporation or any of its subsidiaries (collectively, “ Covered Persons ”), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person’s capacity as a director of the Corporation.

 

6



 

ARTICLE XIII

 

In the event that all, some or any part of any provision contained in this Restated Certificate of Incorporation shall be found by any court of competent jurisdiction to be illegal, invalid or unenforceable (as against public policy or otherwise), such provision shall be enforced to the fullest extent permitted by law and shall be construed as if it had been narrowed only to the extent necessary so as not to be invalid, illegal or unenforceable; the validity, legality and enforceability of the remaining provisions of this Restated Certificate of Incorporation shall continue in full force and effect and shall not be affected or impaired by such illegality, invalidity or unenforceability of any other provision (or any part or parts thereof) of this Restated Certificate of Incorporation.  If and to the extent that any provision contained in this Restated Certificate of Incorporation violates any rule of a securities exchange or automated quotation system on which securities of the Corporation are traded, the Board of Directors is authorized, in its sole discretion, to suspend or terminate such provision for such time or periods of time and subject to such conditions as the Board of Directors shall determine in its sole discretion.

 

7



 

IN WITNESS WHEREOF, this Restated Certificate of Incorporation restates and amends the provisions of the existing Restated Certificate of Incorporation of the Corporation, as amended to date, has been duly adopted in accordance with Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware and has been executed by its Senior Vice President and General Counsel this 30th day of June, 2015.

 

 

 

GLAUKOS CORPORATION

 

 

 

 

 

 

 

By:

/s/ Robert Davis

 

 

Name:

Robert Davis

 

 

Title:

Senior Vice President & General Counsel

 

8


Exhibit 3.2

 

AMENDED AND RESTATED BYLAWS OF

 

GLAUKOS CORPORATION

 

(effective upon the closing of the Corporation’s initial public offering)

 



 

TABLE OF CONTENTS

 

 

 

Page

 

 

 

ARTICLE I — CORPORATE OFFICES

1

 

1.1

REGISTERED OFFICE

1

 

1.2

OTHER OFFICES

1

 

 

 

ARTICLE II — MEETINGS OF STOCKHOLDERS

1

 

2.1

PLACE OF MEETINGS

1

 

2.2

ANNUAL MEETING

1

 

2.3

SPECIAL MEETING

1

 

2.4

ADVANCE NOTICE PROCEDURES

1

 

2.5

NOTICE OF STOCKHOLDERS’ MEETINGS

6

 

2.6

QUORUM

6

 

2.7

ADJOURNED MEETING; NOTICE

6

 

2.8

CONDUCT OF BUSINESS

7

 

2.9

VOTING

7

 

2.10

STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING

7

 

2.11

RECORD DATES

8

 

2.12

PROXIES

8

 

2.13

LIST OF STOCKHOLDERS ENTITLED TO VOTE

9

 

2.14

INSPECTORS OF ELECTION

9

 

 

 

ARTICLE III — DIRECTORS

10

 

3.1

POWERS

10

 

3.2

NUMBER OF DIRECTORS

10

 

3.3

ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS

10

 

3.4

RESIGNATION AND VACANCIES

10

 

3.5

PLACE OF MEETINGS; MEETINGS BY TELEPHONE

11

 

3.6

REGULAR MEETINGS

11

 

3.7

SPECIAL MEETINGS; NOTICE

11

 

3.8

QUORUM; VOTING

12

 

3.9

BOARD OR COMMITTEE ACTION BY WRITTEN CONSENT WITHOUT A MEETING

12

 

3.10

FEES AND COMPENSATION OF DIRECTORS

12

 

 

 

ARTICLE IV — COMMITTEES

13

 

4.1

COMMITTEES OF DIRECTORS

13

 

4.2

COMMITTEE MINUTES

13

 

4.3

MEETINGS AND ACTION OF COMMITTEES

13

 

4.4

SUBCOMMITTEES

14

 

 

 

ARTICLE V — OFFICERS

14

 

5.1

OFFICERS

14

 

5.2

APPOINTMENT OF OFFICERS

14

 

5.3

SUBORDINATE OFFICERS

14

 

5.4

REMOVAL AND RESIGNATION OF OFFICERS

15

 

i



 

 

5.5

VACANCIES IN OFFICES

15

 

5.6

REPRESENTATION OF SHARES OF OTHER CORPORATIONS

15

 

5.7

AUTHORITY AND DUTIES OF OFFICERS

15

 

5.8

THE CHAIRPERSON OF THE BOARD

15

 

5.9

THE VICE CHAIRPERSON OF THE BOARD

16

 

5.10

THE CHIEF EXECUTIVE OFFICER

16

 

5.11

THE PRESIDENT

16

 

5.12

THE VICE PRESIDENTS AND ASSISTANT VICE PRESIDENTS

16

 

5.13

THE SECRETARY AND ASSISTANT SECRETARIES

16

 

5.14

THE TREASURER AND ASSISTANT TREASURERS

17

 

 

 

ARTICLE VI — STOCK

17

 

6.1

STOCK CERTIFICATES; PARTLY PAID SHARES

17

 

6.2

SPECIAL DESIGNATION ON CERTIFICATES

18

 

6.3

LOST, STOLEN OR DESTROYED CERTIFICATES

18

 

6.4

DIVIDENDS

19

 

6.5

TRANSFER OF STOCK

19

 

6.6

STOCK TRANSFER AGREEMENTS

19

 

6.7

REGISTERED STOCKHOLDERS

19

 

 

 

ARTICLE VII — MANNER OF GIVING NOTICE AND WAIVER

19

 

7.1

NOTICE OF STOCKHOLDERS’ MEETINGS

19

 

7.2

NOTICE BY ELECTRONIC TRANSMISSION

20

 

7.3

NOTICE TO STOCKHOLDERS SHARING AN ADDRESS

21

 

7.4

NOTICE TO PERSON WITH WHOM COMMUNICATION IS UNLAWFUL

21

 

7.5

WAIVER OF NOTICE

21

 

 

 

ARTICLE VIII — INDEMNIFICATION

21

 

8.1

INDEMNIFICATION OF DIRECTORS AND OFFICERS IN THIRD PARTY PROCEEDINGS

21

 

8.2

INDEMNIFICATION OF DIRECTORS AND OFFICERS IN ACTIONS BY OR IN THE RIGHT OF THE CORPORATION

22

 

8.3

SUCCESSFUL DEFENSE

22

 

8.4

INDEMNIFICATION OF OTHERS

22

 

8.5

ADVANCED PAYMENT OF EXPENSES

23

 

8.6

LIMITATION ON INDEMNIFICATION

23

 

8.7

DETERMINATION; CLAIM

24

 

8.8

NON-EXCLUSIVITY OF RIGHTS

24

 

8.9

INSURANCE

24

 

8.10

SURVIVAL

25

 

8.11

EFFECT OF REPEAL OR MODIFICATION

25

 

8.12

CERTAIN DEFINITIONS

25

 

 

 

ARTICLE IX — GENERAL MATTERS

25

 

9.1

EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS

25

 

9.2

FISCAL YEAR

26

 

9.3

SEAL

26

 

9.4

CONSTRUCTION; DEFINITIONS

26

 

 

 

ARTICLE X — AMENDMENTS

26

 

ii



 

ARTICLE I — CORPORATE OFFICES

 

1.1                                REGISTERED OFFICE

 

The registered office of Glaukos Corporation (the “ Corporation ”) shall be fixed in the Corporation’s Certificate of Incorporation.  References in these Bylaws to the “Certificate of Incorporation” shall mean the Certificate of Incorporation of the Corporation, as amended from time to time, including the terms of any certificate of designations of any series of Preferred Stock.

 

1.2                                OTHER OFFICES

 

The Corporation’s board of directors (the “ Board of Directors ”) may at any time establish other offices at any place or places where the Corporation is qualified to do business.

 

ARTICLE II — MEETINGS OF STOCKHOLDERS

 

2.1                                PLACE OF MEETINGS

 

Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the Board of Directors.  The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211(a)(2) of the General Corporation Law of the State of Delaware (the “ DGCL ”).  In the absence of any such designation or determination, stockholders’ meetings shall be held at the Corporation’s principal executive office.

 

2.2                                ANNUAL MEETING

 

The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “ Annual Meeting ”) shall be held on such date, at such time, and at such place (if any) within or without the State of Delaware as shall be designated from time to time by the Board of Directors and stated in the Corporation’s notice of the meeting.  At an Annual Meeting, directors shall be elected and any other proper business may be transacted.

 

2.3                                SPECIAL MEETING

 

A special meeting of the stockholders, other than those required by statute, may be called only as provided in the Certificate of Incorporation.

 

2.4                                ADVANCE NOTICE PROCEDURES

 

(i)                                      Advance Notice of Stockholder Business .  At an Annual Meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting.  To be properly brought before an Annual Meeting, business must be brought: (A) pursuant to the Corporation’s proxy materials with respect to such meeting, (B) by or at the direction of the Board of Directors, or (C) by a stockholder of the Corporation who (1) is a stockholder of record at the time of the giving of the notice required by this Section 2.4(i) and on

 



 

the record date for the determination of stockholders entitled to vote at such Annual Meeting and (2) has timely complied in proper written form with the notice procedures set forth in this Section 2.4(i).  In addition, for business to be properly brought before an Annual Meeting by a stockholder, such business must be a proper matter for stockholder action pursuant to these Bylaws and applicable law.  Except for proposals properly made in accordance with Rule 14a-8, or any successor provision, under the Securities and Exchange Act of 1934, as amended, (the “ 1934 Act ”) and included in the notice of meeting given by or at the direction of the Board of Directors, for the avoidance of doubt, clause (C) above shall be the exclusive means for a stockholder to bring business before an Annual Meeting.

 

(a)                                  To comply with clause (C) of Section 2.4(i) above, a stockholder’s notice must set forth all information required under this Section 2.4(i) and must be timely received by the secretary of the Corporation.  To be timely, a stockholder’s notice must be received by the secretary at the principal executive offices of the Corporation not later than the 45th day nor earlier than the 75th day before the one-year anniversary of the date on which the Corporation first mailed its proxy materials or a notice of availability of proxy materials (whichever is earlier) for the preceding year’s annual meeting; provided, however, that in the event that no Annual Meeting was held in the previous year or if the date of an Annual Meeting is advanced by more than 30 days prior to or delayed by more than 60 days after the one-year anniversary of the date of the previous year’s annual meeting, then, for notice by the stockholder to be timely, it must be so received by the secretary not earlier than the close of business on the 120th day prior to such Annual Meeting and not later than the close of business on the later of (i) the 90th day prior to such Annual Meeting, or (ii) the tenth day following the day on which Public Announcement (as defined below) of the date of such Annual Meeting is first made.  In no event shall any adjournment or postponement of an Annual Meeting or the announcement thereof commence a new time period for the giving of a stockholder’s notice as described in this Section 2.4(i)(a).  “ Public Announcement ” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the 1934 Act.

 

(b)                                  To be in proper written form, a stockholder’s notice to the secretary must set forth as to each matter of business the stockholder intends to bring before an Annual Meeting: (1) a brief description of the business intended to be brought before such Annual Meeting and the reasons for conducting such business at such Annual Meeting, (2) the name and address, as they appear on the Corporation’s books, of the stockholder proposing such business and any Stockholder Associated Person (as defined below), (3) the class and number of shares of the Corporation that are held of record or are beneficially owned by the stockholder or any Stockholder Associated Person and any derivative positions held or beneficially held by the stockholder or any Stockholder Associated Person, (4) whether and the extent to which any hedging or other transaction or series of transactions has been entered into by or on behalf of such stockholder or any Stockholder Associated Person with respect to any securities of the Corporation, and a description of any other agreement, arrangement or understanding (including any short position or any borrowing or lending of shares), the effect or intent of which is to mitigate loss to, or to manage the risk or benefit from share price changes for, or to increase or decrease the voting power of, such stockholder or any Stockholder Associated Person with respect to any securities of the Corporation, (5) any material interest of the stockholder or a

 

2



 

Stockholder Associated Person in such business, and (6) a statement whether either such stockholder or any Stockholder Associated Person will deliver a proxy statement and form of proxy to holders of at least the percentage of the Corporation’s voting shares required under applicable law to carry the proposal (such information provided and statements made as required by clauses (1) through (6), a “ Business Solicitation Statement ”).  In addition, to be in proper written form, a stockholder’s notice to the secretary must be supplemented not later than ten days following the record date for notice of the meeting to disclose the information contained in clauses (3) and (4) above as of the record date for notice of the meeting.  For purposes of this Section 2.4, a “ Stockholder Associated Person ” of any stockholder shall mean (i) any person controlling, directly or indirectly, or acting in concert with, such stockholder, (ii) any beneficial owner of shares of stock of the Corporation owned of record or beneficially by such stockholder and on whose behalf the proposal or nomination, as the case may be, is being made, or (iii) any person controlling, controlled by or under common control with such person referred to in the preceding clauses (i) and (ii).

 

(c)                                   Without exception, no business shall be conducted at an Annual Meeting except in accordance with the provisions set forth in this Section 2.4(i) and, if applicable, Section 2.4(ii).  In addition, business proposed to be brought by a stockholder may not be brought before an Annual Meeting if such stockholder or a Stockholder Associated Person, as applicable, takes action contrary to the representations made in the Business Solicitation Statement applicable to such business or if the Business Solicitation Statement applicable to such business contains an untrue statement of a material fact or omits to state a material fact necessary to make the statements therein not misleading.  The chairperson of an Annual Meeting shall, if the facts warrant, determine and declare at such Annual Meeting that business was not properly brought before such Annual Meeting and in accordance with the provisions of this Section 2.4(i), and, if the chairperson should so determine, he or she shall so declare at such Annual Meeting that any such business not properly brought before such Annual Meeting shall not be conducted.

 

(ii)                                   Advance Notice of Director Nominations at an Annual Meeting .  Notwithstanding anything in these Bylaws to the contrary, only persons who are nominated in accordance with the procedures set forth in this Section 2.4(ii) shall be eligible for election or re-election as directors at an Annual Meeting.  Nominations of persons for election or re-election to the Board of Directors of the Corporation shall be made at an Annual Meeting only (A) by or at the direction of the Board of Directors or (B) by a stockholder of the Corporation who (1) was a stockholder of record at the time of the giving of the notice required by this Section 2.4(ii) and on the record date for the determination of stockholders entitled to vote at such Annual Meeting and (2) has complied with the notice procedures set forth in this Section 2.4(ii).  In addition to any other applicable requirements, for a nomination to be made by a stockholder, the stockholder must have given timely notice thereof in proper written form to the secretary of the Corporation.

 

(a)                                  To comply with clause (B) of Section 2.4(ii) above, a nomination to be made by a stockholder must set forth all information required under this Section 2.4(ii) and must be received by the secretary of the Corporation at the principal executive offices of the Corporation at the time set forth in, and in accordance with, the final three sentences of Section 2.4(i)(a) above.

 

3



 

(b)                                  To be in proper written form, such stockholder’s notice to the secretary must set forth:

 

(1)                                  as to each person (a “ nominee ”) whom the stockholder proposes to nominate for election or re­election as a director: (A) the name, age, business address and residence address of the nominee, (B) the principal occupation or employment of the nominee, (C) the class and number of shares of the Corporation that are held of record or are beneficially owned by the nominee and any derivative positions held or beneficially held by the nominee, (D) whether and the extent to which any hedging or other transaction or series of transactions has been entered into by or on behalf of the nominee with respect to any securities of the Corporation, and a description of any other agreement, arrangement or understanding (including any short position or any borrowing or lending of shares), the effect or intent of which is to mitigate loss to, or to manage the risk or benefit of share price changes for, or to increase or decrease the voting power of the nominee, (E) a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by the stockholder, (F) a written statement executed by the nominee acknowledging that as a director of the Corporation, the nominee will owe a fiduciary duty under Delaware law with respect to the Corporation and its stockholders, and (G) any other information relating to the nominee that would be required to be disclosed about such nominee if proxies were being solicited for the election or re- election of the nominee as a director, or that is otherwise required, in each case pursuant to Regulation 14A under the 1934 Act (including without limitation the nominee’s written consent to being named in the proxy statement, if any, as a nominee and to serving as a director if elected or re­ elected, as the case may be); and

 

(2)                                  As to such stockholder giving notice, (A) the information required to be provided pursuant to clauses (2) through (5) of Section 2.4(i)(b) above, and the supplement referenced in the second sentence of Section 2.4(i)(b) above (except that the references to “business” in such clauses shall instead refer to nominations of directors for purposes of this paragraph), and (B) a statement whether either such stockholder or Stockholder Associated Person will deliver a proxy statement and form of proxy to holders of a number of the Corporation’s voting shares reasonably believed by such stockholder or Stockholder Associated Person to be necessary to elect or re-elect such nominee(s) (such information provided and statements made as required by clauses (A) and (B) above, a “ Nominee Solicitation Statement ”).

 

(c)                                   At the request of the Board of Directors, any person nominated by a stockholder for election or re-election as a director must furnish to the secretary of the Corporation (1) that information required to be set forth in the stockholder’s notice of nomination of such person as a director as of a date subsequent to the date on which the notice of such person’s nomination was given and (2) such other information (i) as may reasonably be required by the Corporation to determine the eligibility of such proposed nominee to serve as an independent director or audit committee financial expert of the Corporation under applicable law, securities exchange rule or regulation, or any publicly-disclosed corporate governance guideline or committee charter of the Corporation and (ii) that could be material to a reasonable stockholder’s understanding of the independence, or lack thereof, of such nominee; in the absence of the furnishing of such information if requested, such stockholder’s nomination shall not be considered in proper form pursuant to this Section 2.4(ii).

 

4



 

(d)                                  Without exception, no person shall be eligible for election or re-election as a director of the Corporation at an Annual Meeting unless nominated in accordance with the provisions set forth in this Section 2.4(ii).  In addition, a nominee shall not be eligible for election or re-election if a stockholder or Stockholder Associated Person, as applicable, takes action contrary to the representations made in the Nominee Solicitation Statement applicable to such nominee or if the Nominee Solicitation Statement applicable to such nominee contains an untrue statement of a material fact or omits to state a material fact necessary to make the statements therein not misleading.  The chairperson of an Annual Meeting shall, if the facts warrant, determine and declare at such Annual Meeting that a nomination was not made in accordance with the provisions prescribed by these Bylaws, and if the chairperson should so determine, he or she shall so declare at such Annual Meeting, and the defective nomination shall be disregarded.

 

(iii)                                Advance Notice of Director Nominations for Special Meetings .

 

(a)                                  For a special meeting of stockholders at which directors are to be elected or re-elected, nominations of persons for election or re-election to the Board of Directors shall be made only (1) by or at the direction of the Board of Directors or (2) by any stockholder of the Corporation who (A) is a stockholder of record at the time of the giving of the notice required by this Section 2.4(iii) and on the record date for the determination of stockholders entitled to vote at the special meeting and (B) delivers a timely written notice of the nomination to the secretary of the Corporation that includes the information set forth in Sections 2.4(ii)(b) and (ii)(c) above.  To be timely, such notice must be received by the secretary at the principal executive offices of the Corporation not later than the close of business on the later of the 90th day prior to such special meeting or the tenth day following the day on which Public Announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected or re-elected at such meeting.  A person shall not be eligible for election or re-election as a director at a special meeting unless the person is nominated (i) by or at the direction of the Board of Directors or (ii) by a stockholder in accordance with the notice procedures set forth in this Section 2.4(iii).  In addition, a nominee shall not be eligible for election or re-election if a stockholder or Stockholder Associated Person, as applicable, takes action contrary to the representations made in the Nominee Solicitation Statement applicable to such nominee or if the Nominee Solicitation Statement applicable to such nominee contains an untrue statement of a material fact or omits to state a material fact necessary to make the statements therein not misleading.

 

(b)                                  The chairperson of the special meeting shall, if the facts warrant, determine and declare at the meeting that a nomination or business was not made in accordance with the procedures prescribed by these Bylaws, and if the chairperson should so determine, he or she shall so declare at the meeting, and the defective nomination or business shall be disregarded.

 

(iv)                               Other Requirements and Rights .  In addition to the foregoing provisions of this Section 2.4, a stockholder must also comply with all applicable requirements of state law and of the 1934 Act and the rules and regulations thereunder with respect to the matters set forth in this Section 2.4.  Nothing in this Section 2.4 shall be deemed to affect any rights of:

 

5



 

(a)                                  a stockholder to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a­8 (or any successor provision) under the 1934 Act; or

 

(b)                                  the Corporation to omit a proposal from the Corporation’s proxy statement pursuant to Rule 14a­8 (or any successor provision) under the 1934 Act.

 

2.5                                NOTICE OF STOCKHOLDERS’ MEETINGS

 

Whenever stockholders are required or permitted to take any action at a meeting, a written notice of the meeting shall be given which shall state the place, if any, date and hour of the meeting, the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.  Except as otherwise provided in the DGCL, the Certificate of Incorporation or these Bylaws, the written notice of any meeting of stockholders shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting.

 

2.6                                QUORUM

 

The holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.  Where a separate vote by a class or series or classes or series is required, a majority of the outstanding shares of such class or series or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter, except as otherwise provided by law, the Certificate of Incorporation or these Bylaws

 

If a quorum is not present or represented at any meeting of the stockholders, then either (i) the chairperson of the meeting, or (ii) the stockholders entitled to vote at the meeting, present in person or represented by proxy, shall have power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present or represented.  At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.

 

2.7                                ADJOURNED MEETING; NOTICE

 

When a meeting is adjourned to another time or place, unless these Bylaws otherwise require, notice need not be given of the adjourned meeting if the time, place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken.  At the adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting.  If the adjournment is for more than 30 days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.  If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such adjourned meeting in accordance with Section 213(a) of the DGCL and Section 2.11 of these Bylaws, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting.

 

6



 

2.8                                CONDUCT OF BUSINESS

 

The chairperson of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of business.  The chairperson of any meeting of stockholders shall be designated by the Board of Directors; in the absence of such designation, the chairperson of the board, if any, the chief executive officer (in the absence of the chairperson) or the president (in the absence of the chairperson of the board and the chief executive officer), or in their absence any other executive officer of the Corporation, shall serve as chairperson of the stockholder meeting.

 

2.9                                VOTING

 

The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Section 2.11 of these Bylaws, subject to Section 217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section 218 (relating to voting trusts and other voting agreements) of the DGCL.

 

Except as may be otherwise provided in the Certificate of Incorporation or these Bylaws, each stockholder shall be entitled to one vote for each share of capital stock held by such stockholder.

 

Except as otherwise required by law, the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders.  Except as otherwise required by law, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.  Where a separate vote by a class or series or classes or series is required, in all matters other than the election of directors, the affirmative vote of the majority of shares of such class or series or classes or series present in person or represented by proxy at the meeting shall be the act of such class or series or classes or series, except as otherwise provided by law, the Certificate of Incorporation or these Bylaws.

 

2.10                         STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING

 

Subject to the rights of the holders of the shares of any series of Preferred Stock or any other class of stock or series thereof that have been expressly granted the right to take action by written consent, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders.

 

7



 

2.11                         RECORD DATES

 

In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and which record date shall not be more than 60 nor less than 10 days before the date of such meeting.  If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination.

 

If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held.

 

A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided , however , that the Board of Directors may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with the provisions of Section 213 of the DGCL and this Section 2.11 at the adjourned meeting.

 

In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action.  If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

 

2.12                         PROXIES

 

Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period.  The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section 212 of the DGCL.  A written proxy may be in the form of a telegram, cablegram, or other means of electronic transmission which sets forth or is submitted with information from which it can be determined that the telegram, cablegram, or other means of electronic transmission was authorized by the person.

 

8



 

2.13                         LIST OF STOCKHOLDERS ENTITLED TO VOTE

 

The officer who has charge of the stock ledger of the Corporation shall prepare and make, at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting; provided , however , if the record date for determining the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth day before the meeting date.  The stockholder list shall be arranged in alphabetical order and show the address of each stockholder and the number of shares registered in the name of each stockholder.  The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list.  Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of at least 10 days prior to the meeting (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours, at the Corporation’s principal place of business.  In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation.  If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be examined by any stockholder who is present.  If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting.  Such list shall presumptively determine the identity of the stockholders entitled to vote at the meeting and the number of shares held by each of them.

 

2.14                         INSPECTORS OF ELECTION

 

Before any meeting of stockholders, the Board of Directors shall appoint an inspector or inspectors of election to act at the meeting or its adjournment.  The number of inspectors shall be either one (1) or three (3).  If any person appointed as inspector fails to appear or fails or refuses to act, then the chairperson of the meeting may, and upon the request of any stockholder or a stockholder’s proxy shall, appoint a person to fill that vacancy.

 

Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability.  The inspector or inspectors so appointed and designated shall (i) ascertain the number of shares of capital stock of the Corporation outstanding and the voting power of each share, (ii) determine the shares of capital stock of the Corporation represented at the meeting and the validity of proxies and ballots, (iii) count all votes and ballots, (iv) determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors, and (v) certify their determination of the number of shares of capital stock of the Corporation represented at the meeting and such inspector or inspectors’ count of all votes and ballots.

 

In determining the validity and counting of proxies and ballots cast at any meeting of stockholders of the Corporation, the inspector or inspectors may consider such information as is permitted by applicable law to be so considered.  If there are three (3) inspectors of election, the decision, act or certificate of a majority is effective in all respects as the decision, act or certificate of all.

 

9



 

ARTICLE III — DIRECTORS

 

3.1                                POWERS

 

The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors, except as may be otherwise provided in the DGCL or the Certificate of Incorporation.

 

3.2                                NUMBER OF DIRECTORS

 

The Board of Directors shall consist of one or more members, each of whom shall be a natural person.  Unless the Certificate of Incorporation fixes the number of directors, the number of directors shall be determined from time to time solely by resolution of the Board of Directors.  No reduction of the authorized number of directors shall have the effect of removing any director before that director’s term of office expires.

 

3.3                                ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS

 

Except as provided in Section 3.4 of these Bylaws, each director, including a director elected to fill a vacancy, shall hold office until the expiration of the term for which elected and until such director’s successor is elected and qualified or until such director’s earlier death, resignation or removal.  Directors need not be stockholders unless so required by the Certificate of Incorporation or these Bylaws.  The Certificate of Incorporation or these Bylaws may prescribe other qualifications for directors.

 

3.4                                RESIGNATION AND VACANCIES

 

Any director may resign at any time upon notice given in writing or by electronic transmission to the Corporation; provided , however , that if such notice is given by electronic transmission, such electronic transmission must either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized by the director.  A resignation is effective when the resignation is delivered unless the resignation specifies a later effective date or an effective date determined upon the happening of an event or events.  Acceptance of such resignation shall not be necessary to make it effective.  A resignation which is conditioned upon the director failing to receive a specified vote for reelection as a director may provide that it is irrevocable.  Unless otherwise provided in the Certificate of Incorporation or these Bylaws, when one or more directors resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective.

 

Unless otherwise provided in the Certificate of Incorporation or these Bylaws, vacancies and newly created directorships resulting from any increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single class shall be filled only by a majority of the directors then in office, although less than a quorum, or by a sole remaining director.  If the directors are divided into classes, a person so elected by the directors then in office to fill a vacancy or newly created directorship shall hold office until the next election of the class for which such director shall have been chosen and until his or her successor shall have been duly elected and qualified.

 

10



 

If, at the time of filling any vacancy or any newly created directorship, the directors then in office constitute less than a majority of the whole Board of Directors (as constituted immediately prior to any such increase), the Court of Chancery may, upon application of any stockholder or stockholders holding at least 10% of the voting stock at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any such vacancies or newly created directorships, or to replace the directors chosen by the directors then in office as aforesaid, which election shall be governed by the provisions of Section 211 of the DGCL as far as applicable.

 

3.5                                PLACE OF MEETINGS; MEETINGS BY TELEPHONE

 

The Board of Directors may hold meetings, both regular and special, either within or outside the State of Delaware.

 

Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, members of the Board of Directors, or any committee designated by the Board of Directors, may participate in a meeting of the Board of Directors, or any committee, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.

 

3.6                                REGULAR MEETINGS

 

Regular meetings of the Board of Directors may be held without notice at such time and at such place as shall from time to time be determined by the Board of Directors.

 

3.7                                SPECIAL MEETINGS; NOTICE

 

Special meetings of the Board of Directors for any purpose or purposes may be called at any time by the chairperson of the Board of Directors, the chief executive officer, the president, the secretary or a majority of the authorized number of directors, at such times and places as he or she or they shall designate.

 

Notice of the time and place of special meetings shall be:

 

(i)                                      delivered personally by hand, by courier or by telephone;

 

(ii)                                   sent by United States first-class mail, postage prepaid;

 

(iii)                                sent by facsimile; or

 

(iv)                               sent by electronic mail,

 

directed to each director at that director’s address, telephone number, facsimile number or electronic mail address, as the case may be, as shown on the Corporation’s records.

 

11



 

If the notice is (i) delivered personally by hand, by courier or by telephone, (ii) sent by facsimile or (iii) sent by electronic mail, it shall be delivered or sent at least 24 hours before the time of the holding of the meeting.  If the notice is sent by United States mail, it shall be deposited in the United States mail at least four days before the time of the holding of the meeting.  Any oral notice may be communicated to the director.  The notice need not specify the place of the meeting (if the meeting is to be held at the Corporation’s principal executive office) nor the purpose of the meeting.

 

3.8                                QUORUM; VOTING

 

At all meetings of the Board of Directors, a majority of the total authorized number of directors shall constitute a quorum for the transaction of business.  If a quorum is not present at any meeting of the Board of Directors, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.  A meeting at which a quorum is initially present may continue to transact business notwithstanding the withdrawal of directors, if any action taken is approved by at least a majority of the required quorum for that meeting.

 

The vote of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board of Directors, except as may be otherwise specifically provided by statute, the Certificate of Incorporation or these Bylaws.

 

If the Certificate of Incorporation provides that one or more directors shall have more or less than one vote per director on any matter, every reference in these Bylaws to a majority or other proportion of the directors shall refer to a majority or other proportion of the votes of the directors.

 

3.9                                BOARD OR COMMITTEE ACTION BY WRITTEN CONSENT WITHOUT A MEETING

 

Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee.  Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

 

3.10                         FEES AND COMPENSATION OF DIRECTORS

 

Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, the Board of Directors shall have the authority to fix the compensation of directors.

 

12



 

ARTICLE IV — COMMITTEES

 

4.1                                COMMITTEES OF DIRECTORS

 

The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation.  The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee.  In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.  Any such committee, to the extent provided in the resolution of the Board of Directors or in these Bylaws, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority to (i) approve or adopt, or recommend to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii) adopt, amend or repeal any bylaw of the Corporation.

 

4.2                                COMMITTEE MINUTES

 

Each committee shall keep regular minutes of its meetings and report the same to the Board of Directors when required.

 

4.3                                MEETINGS AND ACTION OF COMMITTEES

 

Meetings and actions of committees shall be governed by, and held and taken in accordance with, the provisions of:

 

(i)                                      Section 3.5 (place of meetings; meetings by telephone);

 

(ii)                                   Section 3.6 (regular meetings);

 

(iii)                                Section 3.7 (special meetings; notice);

 

(iv)                               Section 3.8 (quorum; voting);

 

(v)                                  Section 3.9 (board or committee action by written consent without a meeting); and

 

(vi)                               Section 7.5 (waiver of notice)

 

with such changes in the context of those Bylaws as are necessary to substitute the committee and its members for the Board of Directors and its members.  However :

 

(i)                                      the time of regular meetings of committees may be determined by resolution of the committee;

 

13



 

(ii)                                   special meetings of committees may also be called by resolution of the committee; and

 

(iii)                                notice of special meetings of committees shall also be given to all alternate members, who shall have the right to attend all meetings of the committee.  The Board of Directors may adopt rules for the government of any committee not inconsistent with the provisions of these Bylaws.

 

Any provision in the Certificate of Incorporation providing that one or more directors shall have more or less than one vote per director on any matter shall apply to voting in any committee or subcommittee, unless otherwise provided in the Certificate of Incorporation or these Bylaws.

 

4.4                                SUBCOMMITTEES

 

Unless otherwise provided in the Certificate of Incorporation, these Bylaws or the resolutions of the Board of Directors designating the committee, a committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee.

 

ARTICLE V — OFFICERS

 

5.1                                OFFICERS

 

The officers of the Corporation shall be a president, a secretary and a treasurer.  The Corporation may also have, at the discretion of the Board of Directors, a chairperson of the Board of Directors, a vice chairperson of the Board of Directors, a chief executive officer, a chief financial officer, one or more vice presidents, one or more assistant vice presidents, one or more assistant treasurers, one or more assistant secretaries, and any such other officers as may be appointed in accordance with the provisions of these Bylaws.  Any number of offices may be held by the same person.

 

5.2                                APPOINTMENT OF OFFICERS

 

The Board of Directors shall appoint the officers of the Corporation, except such officers as may be appointed in accordance with the provisions of Section 5.3 of these Bylaws, subject to the rights, if any, of an officer under any contract of employment.  A vacancy in any office because of death, resignation, removal, disqualification or any other cause shall be filled in the manner prescribed in this Section 5 for the regular election to such office.

 

5.3                                SUBORDINATE OFFICERS

 

The Board of Directors may appoint, or empower the chief executive officer or, in the absence of a chief executive officer, the president, to appoint, such other officers and agents as the business of the Corporation may require.  Each of such officers and agents shall hold office for such period, have such authority, and perform such duties as are provided in these Bylaws or as the Board of Directors may from time to time determine.

 

14



 

5.4                                REMOVAL AND RESIGNATION OF OFFICERS

 

Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by an affirmative vote of the majority of the Board of Directors at any regular or special meeting of the Board of Directors or, except in the case of an officer chosen by the Board of Directors, by any officer upon whom such power of removal may be conferred by the Board of Directors.

 

Any officer may resign at any time by giving written or electronic notice to the Corporation; provided , however , that if such notice is given by electronic transmission, such electronic transmission must either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized by the officer.  Any resignation shall take effect at the date of the receipt of that notice or at any later time specified in that notice.  Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall not be necessary to make it effective.  Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party.

 

5.5                                VACANCIES IN OFFICES

 

Any vacancy occurring in any office of the Corporation shall be filled by the Board of Directors or as provided in Section 5.3.

 

5.6                                REPRESENTATION OF SHARES OF OTHER CORPORATIONS

 

The chairperson of the Board of Directors, the president, any vice president, the treasurer, the secretary or assistant secretary of this Corporation, or any other person authorized by the Board of Directors or the president or a vice president, is authorized to vote, represent, and exercise on behalf of this Corporation all rights incident to any and all shares of any other Corporation or corporations standing in the name of this Corporation.  The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.

 

5.7                                AUTHORITY AND DUTIES OF OFFICERS

 

All officers of the Corporation shall respectively have such authority and perform such duties in the management of the business of the Corporation as may be designated from time to time by the Board of Directors and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board of Directors.

 

5.8                                THE CHAIRPERSON OF THE BOARD

 

The chairperson of the board, if any, shall have the powers and duties customarily and usually associated with the office of the chairperson of the board.  The chairperson of the board shall preside at meetings of the stockholders and of the Board of Directors.

 

15



 

5.9                                THE VICE CHAIRPERSON OF THE BOARD

 

The vice chairperson of the board shall have the powers and duties customarily and usually associated with the office of the vice chairperson of the board.  In the case of absence or disability of the chairperson of the board, the vice chairperson of the board shall perform the duties and exercise the powers of the chairperson of the board.

 

5.10                         THE CHIEF EXECUTIVE OFFICER

 

The chief executive officer shall have, subject to the supervision, direction and control of the Board of Directors, ultimate authority for decisions relating to the supervision, direction and management of the affairs and the business of the Corporation customarily and usually associated with the position of chief executive officer, including, without limitation, all powers necessary to direct and control the organizational and reporting relationships within the Corporation.  If at any time the office of the chairperson and vice chairperson of the board shall not be filled, or in the event of the temporary absence or disability of the chairperson of the board and the vice chairperson of the board, the chief executive officer shall perform the duties and exercise the powers of the chairperson of the board unless otherwise determined by the Board of Directors.

 

5.11                         THE PRESIDENT

 

The president shall have, subject to the supervision, direction and control of the Board of Directors, the general powers and duties of supervision, direction and management of the affairs and business of the Corporation customarily and usually associated with the position of president.  The president shall have such powers and perform such duties as may from time to time be assigned to him or her by the Board of Directors, the chairperson of the board or the chief executive officer.  In the event of the absence or disability of the chief executive officer, the president shall perform the duties and exercise the powers of the chief executive officer unless otherwise determined by the Board of Directors.

 

5.12                         THE VICE PRESIDENTS AND ASSISTANT VICE PRESIDENTS

 

Each vice president and assistant vice president shall have such powers and perform such duties as may from time to time be assigned to him or her by the Board of Directors, the chairperson of the board, the chief executive officer or the president.

 

5.13                         THE SECRETARY AND ASSISTANT SECRETARIES

 

(i)                                      The secretary shall attend meetings of the Board of Directors and meetings of the stockholders and record all votes and minutes of all such proceedings in a book or books kept for such purpose.  The secretary shall have all such further powers and duties as are customarily and usually associated with the position of secretary or as may from time to time be assigned to him or her by the Board of Directors, the chairperson of the board, the chief executive officer or the president.

 

16



 

(ii)                                   Each assistant secretary shall have such powers and perform such duties as may from time to time be assigned to him or her by the Board of Directors, the chairperson of the board, the chief executive officer, the president or the secretary.  In the event of the absence, inability or refusal to act of the secretary, the assistant secretary (or if there shall be more than one, the assistant secretaries in the order determined by the Board of Directors) shall perform the duties and exercise the powers of the secretary.

 

5.14                         THE TREASURER AND ASSISTANT TREASURERS

 

(i)                                      The treasurer shall be the principal financial officer of the Corporation and, if a chief financial officer is not appointed, shall also be the chief financial officer of the Corporation.  The treasurer shall have custody of the Corporation’s funds and securities, shall be responsible for maintaining the Corporation’s accounting records and statements, shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation, and shall deposit or cause to be deposited moneys or other valuable effects in the name and to the credit of the Corporation in such depositories as may be designated by the Board of Directors.  The treasurer shall also maintain adequate records of all assets, liabilities and transactions of the Corporation and shall assure that adequate audits thereof are currently and regularly made.  The treasurer shall have all such further powers and duties as are customarily and usually associated with the position of treasurer or chief financial officer, or as may from time to time be assigned to him or her by the Board of Directors, the chairperson, the chief executive officer or the president.

 

(ii)                                   Each assistant treasurer shall have such powers and perform such duties as may from time to time be assigned to him or her by the Board of Directors, the chief executive officer, the president or the treasurer.  In the event of the absence, inability or refusal to act of the treasurer, the assistant treasurer (or if there shall be more than one, the assistant treasurers in the order determined by the Board of Directors) shall perform the duties and exercise the powers of the treasurer.

 

ARTICLE VI — STOCK

 

6.1                                STOCK CERTIFICATES; PARTLY PAID SHARES

 

The shares of the Corporation shall be represented by certificates, provided that the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares.  Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation.  Every holder of stock represented by certificates shall be entitled to have a certificate signed by, or in the name of the Corporation by the chairperson of the Board of Directors or vice-chairperson of the Board of Directors, or the president or a vice-president, and by the treasurer or an assistant treasurer, or the secretary or an assistant secretary of the Corporation representing the number of shares registered in certificate form.  Any or all of the signatures on the certificate may be a facsimile.  In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the date of issue.  The Corporation shall not have power to issue a certificate in bearer form.

 

17



 

The Corporation may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be paid therefor.  Upon the face or back of each stock certificate issued to represent any such partly-paid shares, or upon the books and records of the Corporation in the case of uncertificated partly-paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon shall be stated.  Upon the declaration of any dividend on fully-paid shares, the Corporation shall declare a dividend upon partly-paid shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.

 

6.2                                SPECIAL DESIGNATION ON CERTIFICATES

 

If the Corporation is authorized to issue more than one class of stock or more than one series of any class, then the powers, the designations, the preferences, and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock; provided, however, that, except as otherwise provided in Section 202 of the DGCL, in lieu of the foregoing requirements there may be set forth on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock, a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.  Within a reasonable time after the issuance or transfer of uncertificated stock, the Corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to this section 6.2 or Sections 156, 202(a) or 218(a) of the DGCL or with respect to this section 6.2 a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.  Except as otherwise expressly provided by law, the rights and obligations of the holders of uncertificated stock and the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical.

 

6.3                                LOST, STOLEN OR DESTROYED CERTIFICATES

 

Except as provided in this Section 6.3, no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the Corporation and cancelled at the same time.  The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner’s legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares.

 

18



 

6.4                                DIVIDENDS

 

The Board of Directors, subject to any restrictions contained in the Certificate of Incorporation or applicable law, may declare and pay dividends upon the shares of the Corporation’s capital stock.  Dividends may be paid in cash, in property, or in shares of the Corporation’s capital stock, subject to the provisions of the Certificate of Incorporation.

 

The Board of Directors may set apart out of any of the funds of the Corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve.  Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of the Corporation, and meeting contingencies.

 

6.5                                TRANSFER OF STOCK

 

Transfers of record of shares of stock of the Corporation shall be made only upon its books by the holders thereof, in person or by an attorney duly authorized, and, if such stock is certificated, upon the surrender of a certificate or certificates for a like number of shares, properly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer; provided, however, that such succession, assignment or authority to transfer is not prohibited by the Certificate of Incorporation, these Bylaws, applicable law or contract.

 

6.6                                STOCK TRANSFER AGREEMENTS

 

The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.

 

6.7                                REGISTERED STOCKHOLDERS

 

The Corporation:

 

(i)                                      shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner;

 

(ii)                                   shall be entitled to hold liable for calls and assessments the person registered on its books as the owner of shares; and

 

(iii)                                shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.

 

ARTICLE VII — MANNER OF GIVING NOTICE AND WAIVER

 

7.1                                NOTICE OF STOCKHOLDERS’ MEETINGS

 

Notice of any meeting of stockholders, if mailed, is given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the Corporation’s records.  An affidavit of the secretary or an assistant secretary of the Corporation or of the transfer agent or other agent of the Corporation that the notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein.

 

19



 

7.2                                NOTICE BY ELECTRONIC TRANSMISSION

 

Without limiting the manner by which notice otherwise may be given effectively to stockholders pursuant to the DGCL, the Certificate of Incorporation or these Bylaws, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation or these Bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given.  Any such consent shall be revocable by the stockholder by written notice to the Corporation.  Any such consent shall be deemed revoked if:

 

(i)                                      the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance with such consent; and

 

(ii)                                   such inability becomes known to the secretary or an assistant secretary of the Corporation or to the transfer agent, or other person responsible for the giving of notice.

 

However, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.

 

Any notice given pursuant to the preceding paragraph shall be deemed given:

 

(i)                                      if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice;

 

(ii)                                   if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice;

 

(iii)                                if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (A) such posting and (B) the giving of such separate notice; and

 

(iv)                               if by any other form of electronic transmission, when directed to the stockholder.

 

An affidavit of the secretary or an assistant secretary or of the transfer agent or other agent of the Corporation that the notice has been given by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein.

 

An “ electronic transmission ” means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.

 

20



 

7.3                                NOTICE TO STOCKHOLDERS SHARING AN ADDRESS

 

Except as otherwise prohibited under the DGCL, without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under the provisions of the DGCL, the Certificate of Incorporation or these Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is given.  Any such consent shall be revocable by the stockholder by written notice to the Corporation.  Any stockholder who fails to object in writing to the Corporation, within 60 days of having been given written notice by the Corporation of its intention to send the single notice, shall be deemed to have consented to receiving such single written notice.

 

7.4                                NOTICE TO PERSON WITH WHOM COMMUNICATION IS UNLAWFUL

 

Whenever notice is required to be given, under the DGCL, the Certificate of Incorporation or these Bylaws, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person.  Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given.  In the event that the action taken by the Corporation is such as to require the filing of a certificate under the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful.

 

7.5                                WAIVER OF NOTICE

 

Whenever notice is required to be given to stockholders, directors or other persons under any provision of the DGCL, the Certificate of Incorporation or these Bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice.  Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.  Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders or the Board of Directors, as the case may be, need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the Certificate of Incorporation or these Bylaws.

 

ARTICLE VIII — INDEMNIFICATION

 

8.1                                INDEMNIFICATION OF DIRECTORS AND OFFICERS IN THIRD PARTY PROCEEDINGS

 

Subject to the other provisions of this Article VIII, the Corporation shall indemnify, to the fullest extent permitted by the DGCL, as now or hereinafter in effect, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “ Proceeding ”) (other

 

21



 

than an action by or in the right of the Corporation) by reason of the fact that such person is or was a director of the Corporation or an officer of the Corporation, or while a director of the Corporation or officer of the Corporation is or was serving at the request of the Corporation as a director, officer, employee or agent of another Corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such Proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful.  The termination of any Proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person’s conduct was unlawful.

 

8.2                                INDEMNIFICATION OF DIRECTORS AND OFFICERS IN ACTIONS BY OR IN THE RIGHT OF THE CORPORATION

 

Subject to the other provisions of this Article VIII, the Corporation shall indemnify, to the fullest extent permitted by the DGCL, as now or hereinafter in effect, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that such person is or was a director or officer of the Corporation, or while a director or officer of the Corporation is or was serving at the request of the Corporation as a director, officer, employee or agent of another Corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation; except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

 

8.3                                SUCCESSFUL DEFENSE

 

To the extent that a present or former director or officer of the Corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding described in Section 8.1 or Section 8.2, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith.

 

8.4                                INDEMNIFICATION OF OTHERS

 

Subject to the other provisions of this Article VIII, the Corporation shall have power to indemnify its employees and its agents to the extent not prohibited by the DGCL or other applicable law.  The Board of Directors shall have the power to delegate the determination of whether employees or agents shall be indemnified to such person or persons as the board of determines.

 

22



 

8.5                                ADVANCED PAYMENT OF EXPENSES

 

Expenses (including attorneys’ fees) incurred by an officer or director of the Corporation in defending any Proceeding shall be paid by the Corporation in advance of the final disposition of such Proceeding upon receipt of a written request therefor (together with documentation reasonably evidencing such expenses) and an undertaking by or on behalf of the person to repay such amounts if it shall ultimately be determined that the person is not entitled to be indemnified under this Article VIII or the DGCL.  Such expenses (including attorneys’ fees) incurred by former directors and officers or other employees and agents may be so paid upon such terms and conditions, if any, as the Corporation deems reasonably appropriate and shall be subject to the Corporation’s expense guidelines.  The right to advancement of expenses shall not apply to any claim for which indemnity is excluded pursuant to these Bylaws, but shall apply to any Proceeding referenced in Section 8.6(ii) or 8.6(iii) prior to a determination that the person is not entitled to be indemnified by the Corporation.

 

8.6                                LIMITATION ON INDEMNIFICATION

 

Subject to the requirements in Section 8.3 and the DGCL, the Corporation shall not be obligated to indemnify any person pursuant to this Article VIII in connection with any Proceeding (or any part of any Proceeding):

 

(i)                                      for which payment has actually been made to or on behalf of such person under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid;

 

(ii)                                   for an accounting or disgorgement of profits pursuant to Section 16(b) of the 1934 Act, or similar provisions of federal, state or local statutory law or common law, if such person is held liable therefor (including pursuant to any settlement arrangements);

 

(iii)                                for any reimbursement of the Corporation by such person of any bonus or other incentive-based or equity-based compensation or of any profits realized by such person from the sale of securities of the Corporation, as required in each case under the 1934 Act (including any such reimbursements that arise from an accounting restatement of the Corporation pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the “ Sarbanes-Oxley Act ”), or the payment to the Corporation of profits arising from the purchase and sale by such person of securities in violation of Section 306 of the Sarbanes-Oxley Act), if such person is held liable therefor (including pursuant to any settlement arrangements);

 

(iv)                               initiated by such person against the Corporation or its directors, officers, employees, agents or other indemnitees, unless (a) the Board of Directors authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (b) the Corporation provides the indemnification, in its sole discretion, pursuant to the powers vested in the Corporation under applicable law, (c) otherwise required to be made under Section 8.7 or (d) otherwise required by applicable law; or

 

23



 

(v)                                  if prohibited by applicable law; provided , however , that if any provision or provisions of this Article VIII shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (1) the validity, legality and enforceability of the remaining provisions of this Article VIII (including, without limitation, each portion of any paragraph or clause containing any such provision held to be invalid, illegal or unenforceable, that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (2) to the fullest extent possible, the provisions of this Article VIII (including, without limitation, each such portion of any paragraph or clause containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforcebable.

 

8.7                                DETERMINATION; CLAIM

 

If a claim for indemnification or advancement of expenses under this Article VIII is not paid in full within 90 days after receipt by the Corporation of the written request therefor, the claimant shall be entitled to an adjudication by a court of competent jurisdiction of his or her entitlement to such indemnification or advancement of expenses.  The Corporation shall indemnify such person against any and all expenses that are incurred by such person in connection with any action for indemnification or advancement of expenses from the Corporation under this Article VIII, to the extent such person is successful in such action, and to the extent not prohibited by law.  In any such suit, the Corporation shall, to the fullest extent not prohibited by law, have the burden of proving that the claimant is not entitled to the requested indemnification or advancement of expenses.

 

8.8                                NON-EXCLUSIVITY OF RIGHTS

 

The indemnification and advancement of expenses provided by, or granted pursuant to, this Article VIII shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under the Certificate of Incorporation or any statute, bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office.  The Corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advancement of expenses, to the fullest extent not prohibited by the DGCL or other applicable law.

 

8.9                                INSURANCE

 

The Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another Corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the Corporation would have the power to indemnify such person against such liability under the provisions of the DGCL.

 

24



 

8.10                         SURVIVAL

 

The rights to indemnification and advancement of expenses conferred by this Article VIII shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.

 

8.11                         EFFECT OF REPEAL OR MODIFICATION

 

Any amendment, alteration or repeal of this Article VIII shall not adversely affect any right or protection hereunder of any person in respect of any act or omission occurring prior to such amendment, alteration or repeal.

 

8.12                         CERTAIN DEFINITIONS

 

For purposes of this Article VIII, references to the “ Corporation ” shall include, in addition to the resulting Corporation, any constituent Corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent Corporation, or is or was serving at the request of such constituent Corporation as a director, officer, employee or agent of another Corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Article VIII with respect to the resulting or surviving Corporation as such person would have with respect to such constituent Corporation if its separate existence had continued.  For purposes of this Article VIII, references to “ other enterprises ” shall include employee benefit plans; references to “ fines ” shall include any excise taxes assessed on a person with respect to an employee benefit plan (excluding any “parachute payments” within the meanings of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended); and references to “ serving at the request of the Corporation ” shall include any service as a director, officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “ not opposed to the best interests of the Corporation ” as referred to in this Article VIII.

 

ARTICLE IX — GENERAL MATTERS

 

9.1                                EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS

 

Except as otherwise provided by law, the Certificate of Incorporation or these Bylaws, the Board of Directors may authorize any officer or officers, or agent or agents, to enter into any contract or execute any document or instrument in the name of and on behalf of the Corporation; such authority may be general or confined to specific instances.  Unless so authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.

 

25



 

9.2                                FISCAL YEAR

 

The fiscal year of the Corporation shall be fixed by resolution of the Board of Directors and may be changed by the Board of Directors.

 

9.3                                SEAL

 

The Corporation may adopt a corporate seal, which shall be adopted and which may be altered by the Board of Directors.  The Corporation may use the corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced.

 

9.4                                CONSTRUCTION; DEFINITIONS

 

Unless the context requires otherwise, the general provisions, rules of construction, and definitions in the DGCL shall govern the construction of these Bylaws.  Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, and the term “ person ” includes both an entity and a natural person.

 

ARTICLE X — AMENDMENTS

 

These Bylaws may be adopted, amended or repealed only as provided in the Certificate of Incorporation.

 

26


Exhibit 10.1

 

AMENDED AND RESTATED
PATENT LICENSE AGREEMENT

 

THIS AMENDED AND RESTATED PATENT LICENSE AGREEMENT (“ Amended and Restated Agreement ”) is entered into and effective as of this 30 th  day of June, 2015 (the “ Restatement Date ”), by and between GLAUKOS CORPORATION, a Delaware corporation, having a place of business at 26051 Merit Circle, Suite 103, Laguna Hills, California 92653 (“ GLAUKOS ”), and DOSE MEDICAL CORPORATION, a Delaware corporation, having a place of business at 26051 Merit Circle, Suite 103, Laguna Hills, California 92653 (“ DOSE ”).

 

RECITALS

 

A.                                     GLAUKOS and DOSE have entered into that certain Patent License Agreement dated March 30, 2010, as amended by that certain letter agreement dated July 19, 2012 (the “ Original Agreement ”) under which, among other things, each party has licensed the other party certain rights to certain patent and patent applications; and

 

B.                                     GLAUKOS and DOSE now wish to amend and restate the Original Agreement as set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Original Agreement is hereby amended and restated to read, and the parties hereto agree, as follows:

 

1.                                       DEFINITIONS

 

For purposes of this Agreement, the following terms shall have the meanings set forth below:

 

1.1.                             Agreement ” means the Original Agreement as amended and restated by this Amended and Restated Agreement, as hereafter amended from time to time in accordance with its terms.

 

1.2.                             “Biosensor ” means any system and/or apparatus designed (i) to be implanted in or affixed to the human body (or any part thereof) and (ii) to monitor and/or measure at least one state or condition of the human body (or any part thereof) or any changes or other aspects affecting the human body (or any part thereof).

 

1.3.                             Confidential Information ” means any information that in any way relates to a party, including without limitation information regarding a party’s business and operations, research and development activities, pre-clinical and clinical data, regulatory strategies and submissions, products, customers, employees, financial results and contractual relationships; provided, however, that the term “Confidential Information” shall not include information: (i) that, at the time of disclosure, is generally available to the public; (ii) that, after disclosure hereunder, becomes generally available to the public, except as a result of a breach of this Agreement by the recipient of such information; (iii) that becomes available to the recipient of such information from a third party that is not legally or contractually prohibited by the disclosing party from disclosing such information; or (iv) that the recipient can demonstrate was developed by or for such recipient without the use of any of the Confidential Information of the disclosing party hereunder.

 

1



 

1.4.                             Dose Field of Use ” means (i) any and all applications of a Biosensor and/or (ii) any and all applications for the treatment of any disorder or disease (other than Glaucoma) primarily affecting the posterior segment of the eye (i.e. the back two-thirds of the eye that includes the anterior hyaloid membrane and all of the optical structures behind it: the vitreous humor, retina, choroid, and optic nerve), provided that such applications described in this clause (ii) do not include an apparatus that includes a drainage lumen unless the drainage lumen’s primary purpose is to relieve intraocular pressure caused by the administration of steroids, delivered by an apparatus implanted in or on the eye, to treat a disorder or disease primarily affecting the posterior segment of the eye and not associated with Glaucoma.

 

1.5.                             Dose Licensed Patents ” means any and all patents and patent applications listed in Exhibit A to this Agreement and any and all U.S. and foreign patents and patent applications, as of the Restatement Date or thereafter, that claim priority to one or more of the patents and patent applications listed in Exhibit A , including, but not limited to, all reissues, reexaminations, continuations, continuations-in-part and divisionals of such patents and patent applications; provided, however, that for such continuations-in-part (and foreign counterparts to such continuations-in-part), Dose Licensed Patents only include those claims in the continuations-in-part (and claims in any foreign counterparts to such continuations-in-part) that are entitled to priority to one or more of the patents and patent applications listed in Exhibit A .

 

1.6.                             Effective Date ” means March 30, 2010.

 

1.7.                             Glaukos Field of Use ” means any and all applications for the treatment of (i) Glaucoma, including but not limited to therapies directed toward reducing intraocular pressure and/or reducing the death of retinal ganglion cells (i.e., neuroprotection) associated with Glaucoma) and/or (ii) any disorder or disease primarily affecting the anterior segment of the eye (i.e., the front third of the eye that includes the structures in front of the vitreous humor: the cornea, iris, ciliary body, the lens, the anterior chamber between the posterior surface of the cornea and the iris and the posterior chamber between the iris and the front face of the vitreous); provided that, such applications described in clauses (i) or (ii) above do not include a Biosensor.

 

1.8.                             Glaukos Group 1 Licensed Patents ” means any and all patents and patent applications listed in Exhibit B to this Agreement and any and all U.S. and foreign patents and patent applications, as of the Restatement Date or thereafter, that claim priority to one or more of the patents and patent applications listed in Exhibit B , including, but not limited to, all reissues, reexaminations, continuations, continuations-in-part and divisionals of such patents and patent applications; provided, however, that for such continuations-in-part (and foreign counterparts to such continuations-in-part), Glaukos Group 1 Licensed Patents only include those claims in the continuations-in-part (and claims in any foreign counterparts to such continuations-in-part) that are entitled to priority to one or more of the patents and patent applications listed in Exhibit B .

 

2



 

1.9.                             Glaukos Group 2 Licensed Patents ” means any and all patents and patent applications listed in Exhibit C to this Agreement and any and all U.S. and foreign patents and patent applications, as of the Restatement Date or thereafter, that claim priority to one or more of the patents and patent applications listed in Exhibit C , including, but not limited to all reissues, reexaminations, continuations, continuations-in-part and divisionals of such patents and patent applications; provided, however, that for such continuations-in-part (and foreign counterparts to such continuations-in-part), Glaukos Group 2 Licensed Patents only include those claims in the continuations-in-part (and claims in any foreign counterparts to such continuations-in-part) that are entitled to priority to one or more of the patents and patent applications listed in Exhibit C .

 

1.10.                      Regulatory Information ” means pre-clinical, clinical, manufacturing and testing data, protocols, and chemical, pharmacological, toxicological, pharmaceutical, physical, analytical, safety, efficacy, bioequivalency, quality assurance, quality control and other information and data relating to any investigations, trials and/or the preparation, submission and prosecution of one or more applications filed in connection with obtaining regulatory approval for any product, including but not limited to, with respect to GLAUKOS, information relating to preliminary investigations and the preparation, submission and prosecution of one or more applications filed in connection with obtaining regulatory approval for the iStent® (a/k/a G1 device), iStent Inject™ (a/k/a G2 device), and iStent Supra™ (a/k/a G3 device) including but not limited to FDA application materials, safety and efficacy data, clinical trial protocols and reports, statistical analyses, communications with the FDA, etc.

 

1.11.                      Term of Access ” means the period commencing on the Effective Date and continuing through and including June 30, 2018; provided, however, that the end date of the Term of Access may be earlier as determined (i) by DOSE upon not less than sixty (60) days’ prior written notice to GLAUKOS, (ii) by GLAUKOS upon not less than one hundred eighty (180) days’ prior written notice to DOSE or (c) by mutual agreement of GLAUKOS and DOSE.

 

1.12.                      Valid Claim ” means a claim that (i) in the case of any issued and unexpired patent, has not been dedicated to the public, disclaimed, nor held invalid or unenforceable by a court or other government entity of competent jurisdiction in an unappealed or unappealable decision, or (ii) in the case of any patent application, (a) has not been cancelled, withdrawn or abandoned, without being refiled in another application, in the applicable jurisdiction, (b) shall not have been finally rejected by a governmental entity or other governmental action from which no appeal can be taken and (c) shall not have been pending for more than five (5) years in the United States Patent and Trademark Office or seven (7) years in a foreign patent office.  For purposes of this definition, the time period for which a claim is pending shall begin on the priority date for such claim, and shall continue until such claim is either issued or is no longer deemed to be a Valid Claim in accordance with the preceding sentence regardless of whether such claim is amended or refiled in another application in the applicable jurisdiction.  If a claim of a patent application which ceased to be a Valid Claim under clause (ii) of the preceding sentence due to the passage of time later issues as part of a patent described within clause (i) of the preceding sentence then it shall again be considered to be a Valid Claim effective as of the issuance of such patent.

 

3



 

2.                                       EXCLUSIVE LICENSE FROM DOSE TO GLAUKOS

 

2.1.                             Subject to Section 2.2, DOSE hereby grants to GLAUKOS a limited, exclusive (even as to DOSE), irrevocable, perpetual, fully paid-up, worldwide license under the Dose Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products, and to practice any and all methods, solely in the Glaukos Field of Use.  The license granted to GLAUKOS under this Section 2.1, however, shall not limit DOSE’s right to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any all products and to practice any and all methods under the Dose Licensed Patents within the Dose Field of Use.  The license granted to GLAUKOS under this Section 2.1 includes the right to sublicense, provided that any such sublicense from GLAUKOS be restricted to the Glaukos Field of Use and subject to the terms of this Agreement, including without limitation Section 2.2.

 

2.2.                             Neither GLAUKOS nor its sublicensees shall seek or obtain a label indication in any country for the treatment of any disorder or disease affecting the posterior segment of the eye for any product whose manufacture, use, offer for sale, sale or importation in or to such country would (absent the license granted under Section 2.1 above) infringe a Valid Claim of a Dose Licensed Patent; provided that, the foregoing of this Section 2.2 shall not limit GLAUKOS from seeking or obtaining any label indication for the treatment of Glaucoma or reduction of intraocular pressure and/or reduction of the death of retinal ganglion cells (i.e., neuroprotection).

 

3.                                       EXCLUSIVE LICENSE FROM GLAUKOS TO DOSE

 

3.1.                             Subject to Section 3.2, GLAUKOS hereby grants to DOSE a limited, exclusive (even as to GLAUKOS), irrevocable, perpetual, fully paid-up, worldwide license under the Glaukos Group 1 Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods solely in the Dose Field of Use.  The license granted to DOSE under this Section 3.1, however, shall not limit GLAUKOS’ right to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any all products and to practice any and all methods under the Glaukos Group 1 Licensed Patents within the Glaukos Field of Use.  The license granted to DOSE under this Section 3.1 includes the right to sublicense, provided that any such sublicense from DOSE be restricted to the Dose Field of Use and subject to the terms of this Agreement, including without limitation Section 3.2.

 

3.2.                             Neither DOSE nor its sublicensees shall seek or obtain a label indication in any country for the treatment of any disorder or disease affecting the anterior segment of the eye for any product whose manufacture, use, offer for sale, sale or importation in or to such country would (absent the license granted under Section 3.1 above) infringe a Valid Claim of a Glaukos Group 1 Licensed Patent; provided that, the foregoing of this Section 3.2 shall not limit DOSE from seeking or obtaining any label indication for application(s) of a Biosensor.

 

4



 

4.                                       EXCLUSIVE LICENSE TO DOSE / LICENSE BACK TO GLAUKOS

 

4.1.                             GLAUKOS hereby grants to DOSE an exclusive (even as to GLAUKOS), irrevocable, perpetual, fully paid-up, worldwide license, with the right to sublicense, under the Glaukos Group 2 Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods that fall within the scope of one or more claims of the Glaukos Group 2 Licensed Patents.

 

4.2.                             Subject to Section 4.3, DOSE hereby grants back to GLAUKOS a limited exclusive (even as to DOSE), irrevocable, fully paid-up, perpetual, worldwide sublicense, with the right to sublicense such sublicense rights, under the Glaukos Group 2 Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods solely in the Glaukos Field of Use.  The sublicense to GLAUKOS, however, shall not limit DOSE’s right to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any all products and to practice any and all methods under the Glaukos Group 2 Licensed Patents within the Dose Field of Use.  This sublicense includes the right for GLAUKOS to grant further sublicenses, provided that any such further sublicense be restricted to the Glaukos Field of Use and subject to the terms of this Agreement, including without limitation Section 4.3.

 

4.3.                             Neither GLAUKOS nor its sublicencees shall seek or obtain a label indication in any country for the treatment of any disorder or disease affecting the posterior segment of the eye for any product whose manufacture, use, offer for sale, sale or importation in or to such country would (absent the license granted under Section 4.2 above) infringe a Valid Claim of a Glaukos Group 2 Licensed Patent; provided that, the foregoing of this Section 4.3 shall not limit GLAUKOS from seeking or obtaining any label indication for the treatment of Glaucoma or reduction of intraocular pressure and/or reduction of the death of retinal ganglion cells (i.e., neuroprotection).

 

5.                                       ASSIGNMENT OF RIGHTS

 

5.1.                             Each of GLAUKOS and DOSE shall have the right to assign in whole or in part its rights, obligations and licenses under this Agreement.

 

5.2.                             Each party shall have the right to assign any or all of its patents or other intellectual property licensed to the other party by this Agreement only if such assignment is expressly subject to the continuance of such license.

 

6.                                       REGULATORY APPROVAL; TECHNOLOGY LICENSE

 

6.1.                             Each party shall be solely responsible, at its sole cost and expenses, for identifying and obtaining, including testing or other procedures, any necessary regulatory or safety approvals or certifications (e.g., FDA and safety agencies) required for the marketing and sale by such party of its products in any country.  Nevertheless, each party will cooperate with the other party by providing, upon request, any Regulatory Information in its possession and control that could reasonably assist the other party to obtain approvals or certifications of its products.  Each party will further permit the other party and its sublicensees to expressly reference each party’s Regulatory Information in the other party’s filings to obtain such approvals or certifications of its products.

 

5



 

6.2.                             Each party acknowledges and agrees that Regulatory Information provided by the other party may contain Confidential Information belonging to the other party. Each party shall disclose its Confidential Information to the other party only on a confidential basis subject to the provisions of Section 13.9.  Any use or disclosure of the Confidential Information of a party under this Agreement, including but not limited to any reference by the other party to the Confidential Information of a party in the other party’s filings to obtain approvals or certifications, shall be designated as confidential.

 

6.3.                             GLAUKOS hereby grants to DOSE a non-exclusive, irrevocable, perpetual, fully paid-up, worldwide license, with the right to sublicense, to use (including without limitation the right to copy and create derivative works) any and all works of authorship, know-how, trade secrets, and other proprietary data or information of GLAUKOS (including but not limited to Regulatory Information and Confidential Information of GLAUKOS), existing as of the Effective Date or during the Term of Access, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products, and to practice any and all inventions, within the Dose Field of Use.  From time to time (including without limitation after the Term of Access), upon DOSE’s written request and expense, GLAUKOS shall promptly deliver to DOSE copies of any and all records, documentation and other tangible embodiments (in whatever form or medium) in Glaukos’s possession or control embodying any works of authorship, know-how, trade secrets or other proprietary data or information within the scope of the license rights granted above.

 

6.4.                             DOSE hereby grants to GLAUKOS a non-exclusive, irrevocable, perpetual, fully paid-up, worldwide license, with the right to sublicense, to use (including without limitation the right to copy and create derivative works) any and all works of authorship, know-how, trade secrets, and other proprietary data or information of DOSE (including but not limited to Regulatory Information and Confidential Information of DOSE), existing as the Effective Date and/or during the Term of Access, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products, and to practice any and all inventions, within the Glaukos Field of Use.  From time to time (including without limitation after the Term of Access), upon GLAUKOS’s written request and expense, DOSE shall promptly deliver to GLAUKOS copies of any and all records, documentation and other tangible embodiments (in whatever form or medium) in DOSE’s possession or control embodying any works of authorship, know-how, trade secrets or other proprietary data or information within the scope of the license rights granted above.

 

6.5.                             Notwithstanding anything herein to the contrary, the rights and obligations of each party set forth Sections 6.1, 6.2, 6.3 and 6.4 shall not pertain to any data or other information arising from investigations or clinical trials conducted after the Term of Access but shall continue to pertain to all other Regulatory Information, including but not limited to any regulatory applications filed after the Term of Access to the extent based on data or information existing as of the Effective Date and/or during the Term of Access.

 

6



 

7.                                       OWNERSHIP

 

7.1.                             DOSE acknowledges that GLAUKOS is the sole owner of the Glaukos Group 1 Licensed Patents and Glaukos Group 2 Licensed Patents, and DOSE agrees that it does not obtain any interest in such patents except for the rights granted herein.  DOSE agrees not to take any action challenging or opposing, on any grounds whatsoever, the ownership by GLAUKOS of such patents, or GLAUKOS’ intellectual property rights therein.  Furthermore, DOSE agrees not to contest the validity or enforceability, or to assist or request any third party to contest the validity or enforceability of any of such patents, to the extent and in jurisdictions where permitted by law, in any judicial, governmental, or quasi-governmental suit or proceeding; and not to request reexamination, post grant review, or inter partes review, or assist or request any third party to request reexamination, post grant review, or inter partes review of any of such patents, to the extent and in jurisdictions where permitted by law.

 

7.2.                             GLAUKOS acknowledges that DOSE is the sole owner of the Dose Licensed Patents, and GLAUKOS agrees that it does not obtain any interest in such patents except for the rights granted herein.  GLAUKOS agrees not to take any action challenging or opposing, on any grounds whatsoever, the ownership by DOSE of the Dose Licensed Patents, or DOSE’s intellectual property rights therein.  Furthermore, GLAUKOS agrees not to contest the validity or enforceability, or to assist or request any third party to contest the validity or enforceability of any of the Dose Licensed Patents, to the extent and in jurisdictions where permitted by law, in any judicial, governmental, or quasi-governmental suit or proceeding; and not to request reexamination, post grant review, or inter partes review, or assist or request any third party to request reexamination, post grant review, or inter partes review of any of the Dose Licensed Patents, to the extent and in jurisdictions where permitted by law.

 

7.3.                             DOSE, in its sole discretion and at its own expense, shall control the entire patent process relating to the Dose Licensed Patents and the Glaukos Group 2 Licensed Patents, including without limitation, prosecution of patent applications and maintenance, reexamination, reissue, and extension of patents; provided, however, that DOSE agrees to (i) promptly provide copies of all prosecution documents to GLAUKOS upon request; (ii) provide GLAUKOS an opportunity to contribute to the prosecution of claims relating to the Glaukos Field of Use, including without limitation making suggestions for (A) claims to pursue, (B) claim amendments and (C) responsive arguments, and consider in good faith whether to adopt any such suggestions and contributions in any responsive filing to a patent office; (iii) subject to clause (iv) below, maintain all issued patents and pending patent applications licensed to GLAUKOS, including paying any and all maintenance fees and annuities; and (iv) notify GLAUKOS in writing sixty (60) days prior to the abandonment of any patent or application for a patent licensed to GLAUKOS, and if requested by GLAUKOS, assign such patent or application to GLAUKOS to take action to prevent the abandonment thereof.  Any patent or patent application assigned pursuant to this Section 7.3 shall hereby be licensed back to the DOSE on a non-exclusive, worldwide, irrevocable, perpetual, fully paid-up basis, without the right to sublicense, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods that fall within the scope of such patent or patent application outside of the Glaukos Field of Use.    With respect to the Glaukos Group 2 Licensed Patents, GLAUKOS will, among other things, assist DOSE in exercising its rights hereunder to

 

7



 

control the entire patent process related to the Glaukos Group 2 Patents, and GLAUKOS hereby irrevocably designates and appoints DOSE as its agent and attorneys-in-fact, coupled with an interest, to act for and on GLAUKOS’ behalf to execute and file any document and to do all other lawfully permitted acts to further the foregoing provisions of this Section 7.3 with the same legal force and effect as if executed by GLAUKOS.

 

7.4.                             GLAUKOS, in its sole discretion and at its own expense, shall control the entire patent process relating to the Glaukos Group 1 Licensed Patents, including without limitation, prosecution of patent applications and maintenance, reexamination, reissue, and extension of patents; provided, however, that GLAUKOS agrees to (i) promptly provide copies of all prosecution documents to DOSE upon request; (ii) provide DOSE an opportunity to contribute to the prosecution of claims relating to the Dose Field of Use, including without limitation making suggestions for (A) claims to pursue, (B) claim amendments and (C) responsive arguments, and consider in good faith whether to adopt any such suggestions and contributions in any responsive filing to a patent office; (iii) subject to clause (iv) below, maintain all issued patents and pending patent applications licensed to DOSE, including paying any and all maintenance fees and annuities; and (iv) notify DOSE in writing sixty (60) days prior to the abandonment of any patent or application for a patent licensed to DOSE, and if requested by DOSE, assign such patent or application to DOSE to take action to prevent the abandonment thereof.  Any patent or patent application assigned pursuant to this Section 7.4 shall hereby be licensed back to GLAUKOS on a non-exclusive, worldwide, irrevocable, perpetual, fully paid-up basis, without the right to sublicense, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods that fall within the scope of such patent or patent application outside of the Dose Field of Use.

 

8.                                       TERM

 

8.1.                             This Agreement shall remain in effect until the expiration date of the last expiring of the Dose Licensed Patents, Glaukos Group 1 Licensed Patents and Glaukos Group 2 Licensed Patents.

 

8.2.                             Notwithstanding the foregoing, Sections 1, 5, 6, 8.2, 11, 12 and 13 shall survive any expiration of this Agreement.

 

9.                                       ENFORCEMENT OF PATENTS

 

9.1.                             Each party agrees that if it becomes aware of any infringement of any of the rights belonging to the other party that are subject of this Agreement, it will promptly disclose such information to the other party.

 

9.2.                             Subject to Sections 9.3 and 9.4, each party shall have the sole and exclusive right, but not the obligation, to bring, prosecute and control any action or proceeding, at its expense, to enforce or defend any patents owned by such party against any infringer.

 

9.3.                             GLAUKOS shall have the sole and exclusive right, but not the obligation, to bring, prosecute and control any action or proceeding, at its expense, to enforce or defend the Dose Licensed Patents and the Glaukos Group 2 Licensed Patents solely in the Glaukos Field of Use.

 

8



 

9.4.                             DOSE shall have the sole and exclusive right, but not the obligation, to bring, prosecute and control any action or proceeding, at its expense, to enforce or defend the Glaukos Group 1 Licensed Patents in the DOSE Field of USE and the Glaukos Group 2 Licensed Patents in any and all applications other than the Glaukos Field of Use.

 

9.5.                             In the event of any action or proceeding under this Section 9, each party agrees to reasonably cooperate with the party taking such action and, at the request of the party taking such action, to give such party all needed information and assistance to file and prosecute such action or proceeding; provided that the acting party shall promptly reimburse the assisting party for all verified out-of-pocket expenses incurred in providing such assistance.  In connection with the foregoing, with respect to any legal action brought under Sections 9.3 or 9.4, each party agrees to join in such action (as necessary to provide standing for such action based on such party’s ownership of the patents at issue) as a party plaintiff if requested to do so by the other party taking such action at such other party’s expense.

 

9.6.                             In resolving any action or proceeding brought by DOSE or GLAUKOS under Sections 9.3 or 9.4, the acting party shall not settle any claim or enter into any other voluntary disposition of the action or proceeding that (i) admits that any third party product, which is outside the scope of such acting party’s exclusive license rights hereunder, does not infringe an asserted patent; (ii) admits that any asserted patent is invalid or unenforceable as to any claim contained therein (provided this clause (ii) shall not apply to DOSE’s enforcement or defense of the Glaukos Group 2 Licensed Patents with respect to claims outside the Glaukos Field of Use); (iii) settles any claim as to any patent rights exclusively licensed to the other party hereunder or (iv) would require the other party to be subject to an injunction or to make a monetary payment or would otherwise adversely affect the other party’s rights hereunder, in each case of clauses (i), (ii), (iii) and (iv) above without the other party’s prior written consent.  Any and all damages, settlement amounts or other consideration obtained by a party to the extent arising as a result of its enforcement or defense of its patent rights pursuant to Sections 9.3 or 9.4, respectively, shall go to such party after reimbursement of any expenses respectively incurred by the parties in accordance with this Section 9 in connection with such enforcement or defense.

 

9.7.                             If DOSE with respect to the Dose Licensed Patents or the Glaukos Group 2 Licensed Patents or GLAUKOS with respect to the Glaukos Group 1 Licensed Patents desires to participate in an action brought by the other party under Sections 9.3 or 9.4, respectively, it shall have the right to do so at its own expense; provided such participation is limited to protecting its patent rights licensed hereunder or owned by it (subject to the exclusive licenses granted herein).  The party taking legal action under Sections 9.3 or 9.4 shall consider in good faith any and all concerns or comments by DOSE or GLAUKOS (as the case may be) in exercising its rights under the foregoing sentence.

 

9



 

9.8.                             In resolving any action or proceeding brought by DOSE or GLAUKOS under Section 9.2, the acting party shall not settle any claim or enter into any other voluntary disposition of the action or proceeding that (i) admits that any third party product, which is within the scope of the other party’s exclusive license rights hereunder, does not infringe an asserted patent; (ii) admits that any asserted patent is invalid or unenforceable as to claims within the other party’s exclusive license rights hereunder; (iii) settles any claim as to any patent rights exclusively licensed to the other party: or (iv) would require the other party to be subject to an injunction or to make a monetary payment or would otherwise adversely affect the other party’s rights hereunder, in each case of clauses (i), (ii), (iii) and (iv) above, without the other party’s prior written consent.  Any and all damages, settlement amounts or other consideration obtained by a party to the extent arising as a result of its enforcement or defense of its patent rights pursuant to Sections 9.2 shall go to such party after reimbursement of any expenses respectively incurred by the parties in accordance with this Section 9 in connection with such enforcement or defense.

 

10.                                PATENT MARKING

 

Each party agrees to mark, and to require its licensees or sublicensees to mark, each product that is made, used, sold or imported pursuant to the provisions herein with a patent notice in compliance with the applicable statutory requirements.

 

11.                                NO REPRESENTATIONS AND WARRANTIES

 

11.1.                      EXCEPT AS EXPRESSLY STATED HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES WHATSOEVER TO THE OTHER PARTY UNDER THIS AGREEMENT, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND ALL SUCH WARRANTIES ARE HEREBY EXPRESSLY EXCLUDED AND DISCLAIMED TO THE FULLEST EXTENT ALLOWED BY APPLICABLE LAW.

 

11.2.                      Without limiting Section 11.1, nothing in this Agreement shall be construed as a warranty or representation by GLAUKOS to DOSE as to the scope or validity of the Glaukos Group 1 Licensed Patents or Glaukos Group 2 Licensed Patents, or that anything made, used, sold or otherwise disposed of under the rights granted in this Agreement is or will be free from infringement of patents of third parties.

 

11.3.                      Without limiting Section 11.1, nothing in this Agreement shall be construed as a warranty or representation by DOSE to GLAUKOS as to the scope or validity of the Dose Licensed Patents, or that anything made, used, sold or otherwise disposed of under the rights granted in this Agreement is or will be free from infringement of patents of third parties.

 

12.                                NOTICES

 

12.1.                      In the event that either GLAUKOS or DOSE sublicenses or assigns any of the rights, obligations or licenses provided under this Agreement or assigns any of the patents licensed hereunder, the assigning or sublicensing party must promptly notify the other party and must identify the third party to whom such assignment or sublicense has been made, including providing a name and contact information of a representative of such third party and a reasonable description of the rights so sublicensed or assigned and/or a list of the patents so assigned.

 

10



 

12.2.                      Any notice, request, demand, or other communication required or permitted to be given under this Agreement shall be in writing and addressed to its addressee at the address set forth above, or such address as a party may specify from time to time.

 

12.3.                      Such notice, request, demand, or other communication shall be deemed to have been duly given (i) at the time of delivery when hand delivered to the other party; or (ii) at the time of confirmed transmission when sent by facsimile at the address and number set forth below, provided that a confirmation copy is sent by overnight or registered or certified mail within twenty-four (24) hours after the fax transmission (any notice given by facsimile shall be deemed received on the next business day if such notice is received after 5:00 p.m. (recipient’s time) or on a non-business day); or (iii) at the time of delivery, or of attempted delivery in the event that delivery cannot be completed due to no fault of the sender, when sent by registered or certified mail or by overnight courier service.

 

13.                                GENERAL PROVISIONS

 

13.1.                      The parties hereby agree that no agency, joint venture or partnership is created by this Agreement, and that neither party shall incur obligations in the name of the other party, except as expressly set forth in this Agreement.

 

13.2.                      This Agreement shall be governed and construed in accordance with the laws of the State of California, and the parties agree that it is executed and delivered in that state.  In the event that any legal action becomes necessary to enforce or interpret the terms of this Agreement, the parties agree that such action shall be brought in the United States District Court for the Central District of California, or in the State Court for the County of Orange, California, and the parties hereby submit to the exclusive jurisdiction of said Courts.  In the event that any legal action becomes necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled, in addition to its court costs or arbitration fees, to such reasonable attorneys’ fees, expert witness fees, and other litigation expenses as shall be fixed by a court of competent jurisdiction.

 

13.3.                      If any provision of this Agreement should be held to be void or unenforceable, in whole or in part, the court or tribunal so holding shall reform the provision to make it enforceable while maintaining the spirit and goal of the provision, and if the court or tribunal finds it cannot so reform that provision, such provision or part thereof shall be treated as severable, leaving valid the remainder of this Agreement.

 

13.4.                      This Agreement, including its exhibits and all documents referenced herein, constitutes the entire understanding and agreement of the parties as to the subject matter herein, and there are no representations, warranties, promises, or undertakings other than those contained herein.  As to the subject matter hereof, this Agreement supersedes and cancels all previous agreements between the parties hereto.  No course of conduct or dealing between the parties shall act as a modification or waiver of any provision of this Agreement, and no waiver or modification of any of the terms or provisions of this Agreement, or failure or delay on the part of either party hereto in insisting upon or enforcing or resorting to any of its powers, rights, remedies, or options hereunder, and no partial or single exercise thereof, shall constitute a waiver of any such powers, rights, remedies or options, unless such waiver be in writing and signed by the party to be charged.

 

11



 

13.5.                      This Agreement shall be binding upon the parties hereto and their respective subsidiaries, affiliates, heirs, legal representatives, successors and permitted assigns.

 

13.6.                      The terms of this Agreement have been negotiated by the parties hereto and the language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent.  This Agreement shall be construed without regard to any presumption or rule requiring construction against the party causing such instrument or any portion thereof to be drafted, or in favor of the party receiving a particular benefit under the Agreement.  No rule of construction will be applied against any party.

 

13.7.                      The headings in this Agreement are intended for convenience only, and shall not be used to interpret the meaning of this Agreement or to determine the rights of the parties.

 

13.8.                      The parties agree that they shall, at any time and from time to time, on the written request of either party, execute and deliver promptly, at the requesting parties’ expense, all such further documents and instruments and shall do or procure to be done, all such further acts and things as may, from time to time, reasonably be required for the purpose of giving full effect to the provisions of this Agreement.

 

13.9.                      From time to time prior to the Effective Date and thereafter, each party hereto has disclosed or may disclose its Confidential Information to the other party.  In addition each party may, from time to time, obtain or have access to the other party’s Confidential Information.  Each party shall maintain (and cause its employees and contractors to maintain) the confidentiality of the other party’s Confidential Information and not to use or disclose such Confidential Information except as required to perform its obligations in accordance with this Agreement or as permitted hereby or by the disclosing party in writing.  If compelled to disclose any Confidential Information by judicial or administrative process or by requirement of law, the receiving party shall promptly notify the disclosing party in writing and, if legal protection is not obtained, may disclose only that portion of such information that is legally required to be disclosed as advised by counsel; provided that the receiving party shall exercise commercially reasonable efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.  Because of the unique nature of the Confidential Information, the parties understand and agree that the disclosing party will suffer irreparable harm in the event that a party which receives such disclosing party’s Confidential Information fails to comply with any of its obligations hereunder and that monetary damages will be inadequate to compensate disclosing party for such breach.  Accordingly, each party agrees that the disclosing party shall, in addition to any other remedies available to it at law or in equity, be entitled to seek injunctive relief to enforce the terms hereof.  Upon request of the disclosing party, unless the receiving party has a continuing right to use such Confidential Information pursuant to a license granted hereunder, the receiving party agrees to return to the disclosing party all Confidential Information of the disclosing party, or, at the receiving party’s option destroy such Confidential Information and, thereafter, certify immediately to the disclosing party that all such Confidential Information has been returned or destroyed.

 

12



 

IN WITNESS WHEREOF, the parties have caused this Amended and Restated Agreement to be executed, effective as of the Restatement Date.

 

 

 

GLAUKOS CORPORATION

 

 

 

 

Dated: June 30, 2015

By:

/s/ THOMAS W. BURNS

 

 

 

Printed Name:

Thomas W. Burns

 

 

 

Title:

President & CEO

 

 

 

 

 

DOSE MEDICAL CORPORATION

 

 

 

 

Dated: June 30, 2015

By:

/s/ RICHARD L. HARRISON

 

 

 

Printed Name:

Richard L. Harrison

 

 

 

Title:

Chief Financial Officer

 

13



 

EXHIBIT A — DOSE LICENSED PATENTS

 

(Status as of June 30, 2015)

 

KMOB
Ref. No.
DOSE.

 

Title of Invention

 

Country

 

Status

 

Patent
No

 

Issued:

1C3CP1

 

OCULAR IMPLANT WITH THERAPEUTIC AGENTS AND METHODS THEREOF

 

US

 

Issued

 

7708711

 

05/04/10

1C3CP1C1

 

OCULAR IMPLANT WITH THERAPEUTIC AGENTS AND METHODS THEREOF

 

US

 

Issued

 

8348877

 

01/08/13

001VRAU

 

APPARATUS AND METHOD FOR TREATING OCULAR DISORDERS

 

AU

 

Issued

 

2006200392

 

11/25/09

001VR2AU

 

APPARATUS AND METHOD FOR TREATING GLAUCOMA

 

AU

 

Issued

 

2009202842

 

04/26/12

001AUD3

 

APPARATUS AND METHOD FOR TREATING GLAUCOMA

 

AU

 

Issued

 

2012201744

 

12/4/14

001JPD2

 

OCULAR IMPLANT WITH THERAPEUTIC DRUG

 

JP

 

Pending

 

 

 

 

5C1CP1

 

IMPLANT WITH INTRAOCULAR PRESSURE SENSOR FOR GLAUCOMA TREATMENT

 

US

 

Issued

 

7678065

 

03/16/10

5CCP1DV1

 

METHOD OF MONITORING INTRAOCULAR PRESSURE AND TREATING AN OCULAR DISORDER

 

US

 

Issued

 

8142364

 

03/27/12

5CCPDD

 

SYSTEM AND METHOD OF MONITORING INTRAOCULAR PRESSURE AND TREATING AN OCULAR DISORDER

 

US

 

Pending

 

 

 

 

011QAUD2

 

DEVICES AND METHODS FOR GLAUCOMA TREATMENT

 

AU

 

Pending

 

 

 

 

044A

 

INTRAOCULAR PHYSIOLOGICAL SENSOR

 

US

 

Pending

 

 

 

 

044WO

 

INTRAOCULAR PHYSIOLOGICAL SENSOR

 

WO

 

Pending

 

 

 

 

045A

 

IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME

 

US

 

Pending

 

 

 

 

045P1WO

 

IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME

 

WO

 

Pending

 

 

 

 

049PR3

 

INTRAOCULAR DRUG DELIVERY IMPLANT

 

US

 

Pending

 

 

 

 

001P1C2

 

OCULAR IMPLANT WITH THERAPEUTIC AGENTS AND METHODS THEREOF

 

US

 

Pending

 

 

 

 

 

A- 1



 

KMOB
Ref. No.
DOSE.

 

Title of Invention

 

Country

 

Status

 

Patent
No

 

Issued:

019NP

 

DRUG ELUTING OCULAR IMPLANT

 

US

 

Pending

 

 

 

 

019EP

 

DRUG ELUTING OCULAR IMPLANT

 

EP

 

Pending

 

 

 

 

032A

 

INTRAOCULAR PHYSIOLOGICAL SENSOR

 

US

 

Pending

 

 

 

 

032EP

 

INTRAOCULAR PHYSIOLOGICAL SENSOR

 

EP

 

Pending

 

 

 

 

036NP

 

DRUG ELUTING OCULAR IMPLANT

 

US

 

Pending

 

 

 

 

036AU

 

DRUG ELUTING OCULAR IMPLANT

 

AU

 

Pending

 

 

 

 

036CA

 

DRUG ELUTING OCULAR IMPLANT

 

CA

 

Pending

 

 

 

 

036CN

 

DRUG ELUTING OCULAR IMPLANT

 

CN

 

Pending

 

 

 

 

036EP

 

DRUG ELUTING OCULAR IMPLANT

 

EP

 

Pending

 

 

 

 

036IN

 

DRUG ELUTING OCULAR IMPLANT

 

IN

 

Pending

 

 

 

 

036JP

 

DRUG ELUTING OCULAR IMPLANT

 

JP

 

Pending

 

 

 

 

036JPD1

 

DRUG ELUTING OCULAR IMPLANT

 

JP

 

Pending

 

 

 

 

037NP

 

UVEOSCLERAL DRUG DELIVERY IMPLANT AND METHODS FOR IMPLANTING THE SAME

 

US

 

Pending

 

 

 

 

053PR

 

IMPLANTS FOR RELEASE OF STABLE DRUG FORMULATIONS TO THE EYE

 

US

 

Pending

 

 

 

 

 

A- 2



 

EXHIBIT B — GLAUKOS GROUP 1 LICENSED PATENTS

 

(Status as of June 30, 2015)

 

KMOB
Ref No.
GLAUKO

 

Title of Invention

 

Country

 

Status

 

Patent No.

 

Issued

001A

 

APPARATUS AND METHOD FOR TREATING GLAUCOMA

 

US

 

Issued

 

6638239

 

10/28/03

001C1

 

APPARATUS AND METHOD FOR TREATING GLAUCOMA

 

US

 

Issued

 

6955656

 

10/18/05

001C2

 

L-SHAPED IMPLANT WITH BI-DIRECTIONAL FLOW

 

US

 

Issued

 

6780164

 

8/24/04

001C4

 

IMPLANT WITH ANCHOR

 

US

 

Issued

 

7297130

 

11/20/07

001CP1

 

GLAUCOMA TREATMENT DEVICE

 

US

 

Issued

 

6736791

 

5/18/04

001VAU

 

APPARATUS AND METHOD FOR TREATING GLAUCOMA

 

AU

 

Issued

 

2001245522

 

2/10/06

001VCA

 

APPARATUS AND METHOD FOR TREATING GLAUCOMA

 

CA

 

Issued

 

2404037

 

10/14/14

001VCAD1

 

APPARATUS AND METHOD FOR TREATING AN OCULAR DISORDER

 

CA

 

Pending

 

 

 

 

001VEP

 

APPARATUS FOR TREATING GLAUCOMA

 

DE, FR, GB

 

Issued

 

1278492

 

4/29/09

001EPD2

 

IMPLANT FOR TREATING OCULAR DISORDERS

 

EP

 

Pending

 

 

 

 

001VREP

 

APPARATUS AND METHOD FOR TREATING GLAUCOMA

 

DE, FR, GB

 

Issued

 

2078516

 

01/02/13

001VJP

 

APPARATUS AND METHOD FOR TREATING GLAUCOMA

 

JP

 

Issued

 

3985019

 

7/20/07

001VRJP

 

APPARATUS AND METHOD FOR TREATING GLAUCOMA

 

JP

 

Issued

 

5255214

 

4/26/2013

011A

 

GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT

 

US

 

Issued

 

7135009

 

11/14/06

011C1

 

IMPLANT AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS

 

US

 

Issued

 

7563241

 

7/21/09

011C1C1

 

SYSTEM FOR TREATING OCULAR DISORDERS AND METHODS THEREOF

 

US

 

Issued

 

8075511

 

12/13/11

011C1D2C

 

OCULAR IMPLANT DELIVERY SYSTEM AND METHODS THEREOF

 

US

 

Pending

 

 

 

 

011C1DV1

 

SELF-TREPHINING IMPLANT AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS

 

US

 

Issued

 

8062244

 

11/22/11

011C1DV2

 

OCULAR IMPLANT DELIVERY SYSTEM AND METHODS THEREOF

 

US

 

Issued

 

7857782

 

12/28/10

 

B- 1



 

KMOB
Ref No.
GLAUKO

 

Title of Invention

 

Country

 

Status

 

Patent No.

 

Issued

011C4

 

OCULAR IMPLANT SYSTEMS

 

US

 

Issued

 

8579846

 

11/12/13

011C5

 

OCULAR IMPLANT SYSTEMS

 

US

 

Pending

 

 

 

 

011C6

 

OCULAR IMPLANT SYSTEMS

 

US

 

Pending

 

 

 

 

011CP1

 

DEVICES AND METHODS FOR TREATMENT OF OCULAR DISORDERS

 

US

 

Issued

 

7867186

 

01/11/11

011CP3

 

OCULAR IMPLANTS WITH ANCHORS AND METHODS THEREOF

 

US

 

Issued

 

7431710

 

10/7/08

011QAU

 

DEVICES AND METHODS FOR GLAUCOMA TREATMENT

 

AU

 

Issued

 

2004264913

 

12/08/11

011QAUD1

 

DEVICES AND METHODS FOR GLAUCOMA TREATMENT

 

AU

 

Pending

 

 

 

 

011QCA

 

DEVICES AND METHODS FOR GLAUCOMA TREATMENT

 

CA

 

Issued

 

2530234

 

11/25/14

011QEP

 

DEVICES AND METHODS FOR GLAUCOMA TREATMENT

 

DE, ES, FR, GB, IT

 

Issued

 

1651291

 

3/13/2013

011QEPD1

 

DEVICES AND METHODS FOR GLAUCOMA TREATMENT

 

DE, ES, FR, GB, IT

 

Issued

 

2351589

 

11/6/2013

011QJP

 

DEVICES AND METHODS FOR GLAUCOMA TREATMENT

 

JP

 

Issued

 

5249513

 

4/19/2013

011QJPD1

 

DEVICES FOR GLAUCOMA TREATMENT

 

JP

 

Issued

 

5698198

 

2/20/15

011QJPD2

 

DEVICES FOR GLAUCOMA TREATMENT

 

JP

 

Pending

 

 

 

 

011VAU

 

GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT

 

AU

 

Issued

 

2002258754

 

11/30/06

011VCA

 

GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT

 

CA

 

Issued

 

2442652

 

01/04/11

011VCAD1

 

NON-LINEAR DELIVERY DEVICE AND OCULAR IMPLANT WITH CUTTING MEMBER

 

CA

 

Issued

 

2718294

 

6/17/2014

011VEP

 

GLAUCOMA STENT FOR GLAUCOMA TREATMENT

 

DE, FR, GB

 

Issued

 

1418868

 

3/26/08

011VEPD2

 

SYSTEM FOR TREATING OCULAR DISORDERS

 

DE, FR, GB

 

Issued

 

2263621

 

5/20/15

011VEPD3

 

SYSTEM FOR TREATING OCULAR DISORDERS

 

EP

 

Pending

 

 

 

 

 

B- 2



 

KMOB
Ref No.
GLAUKO

 

Title of Invention

 

Country

 

Status

 

Patent No.

 

Issued

011VJP

 

GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT

 

JP

 

Issued

 

4264704

 

2/27/09

011VR2AU

 

IMPLANT AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS

 

AU

 

Issued

 

2009251058

 

12/5/2013

011VRAU

 

IMPLANT AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS

 

AU

 

Issued

 

2006236060

 

1/7/10

011VRCA

 

SYSTEM AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS

 

CA

 

Issued

 

2683224

 

12/2/14

011VRJP

 

SYSTEM FOR TREATMENT OF OCULAR DISORDERS

 

JP

 

Issued

 

5255402

 

4/26/2013

011JPD2

 

SYSTEM FOR TREATMENT OF OCULAR DISORDERS

 

JP

 

Pending

 

 

 

 

011XEU

 

GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT

 

EU

 

Issued

 

000097431-0001

 

12/27/05

011XEU2

 

GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT

 

EU

 

Issued

 

000097431-0002

 

12/27/05

011XEU3

 

GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT

 

EU

 

Issued

 

000097431-0003

 

12/27/05

013A

 

MEDICAL DEVICE AND METHODS OF USE FOR GLAUCOMA TREATMENT

 

US

 

Issued

 

7094225

 

8/22/06

013C1

 

MEDICAL DEVICE AND METHODS OF USE FOR GLAUCOMA TREATMENT

 

US

 

Issued

 

7273475

 

9/25/07

013C1DV1

 

OCULAR IMPLANT WITH DOUBLE ANCHOR MECHANISM

 

US

 

Issued

 

8337445

 

12/25/12

017A

 

GLAUCOMA STENT FOR TREATING GLAUCOMA AND METHODS OF USE

 

US

 

Issued

 

7331984

 

2/19/08

017C1

 

IMPLANT DELIVERY SYSTEM AND METHODS THEREOF FOR TREATING OCULAR DISORDERS

 

US

 

Pending

 

 

 

 

017C2

 

IMPLANT DELIVERY SYSTEM AND METHODS THEREOF FOR TREATING OCULAR DISORDERS

 

US

 

Issued

 

7879079

 

02/01/11

020A

 

FLUID INFUSION METHODS FOR GLAUCOMA TREATMENT

 

US

 

Issued

 

7186232

 

3/6/07

022A

 

COMBINED TREATMENT FOR CATARACT AND GLAUCOMA TREATMENT

 

US

 

Issued

 

7163543

 

1/16/07

 

B- 3



 

KMOB
Ref No.
GLAUKO

 

Title of Invention

 

Country

 

Status

 

Patent No.

 

Issued

022C1

 

COMBINED TREATMENT FOR CATARACT AND GLAUCOMA TREATMENT

 

US

 

Issued

 

7951155

 

5/31/11

034A

 

TARGETED STENT PLACEMENT AND MULTI-STENT THERAPY

 

US

 

Issued

 

7192412

 

3/20/07

035A

 

OCULAR IMPLANT WITH ANCHOR AND MULTIPLE OPENINGS

 

US

 

Issued

 

7488303

 

2/10/09

035C2

 

OCULAR IMPLANT WITH ANCHOR AND MULTIPLE OPENINGS

 

US

 

Pending

 

 

 

 

035DV1

 

OCULAR IMPLANT WITH ANCHORING MECHANISM AND MULTIPLE OUTLETS

 

US

 

Issued

 

8007459

 

8/30/11

044DA

 

SURGICAL HANDPIECE

 

US

 

Issued

 

DES490152

 

5/18/04

044XEU

 

SURGICAL INSTRUMENTS

 

EU

 

Issued

 

000071071-0001

 

12/9/03

044XEU2

 

SURGICAL INSTRUMENTS

 

EU

 

Issued

 

000071071-0002

 

12/9/03

044XEU3

 

SURGICAL INSTRUMENTS

 

EU

 

Issued

 

000071071-0003

 

12/9/03

099A

 

UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME

 

US

 

Issued

 

8506515

 

08/13/13

099C1

 

UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME

 

US

 

Pending

 

 

 

 

099AUD1

 

UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME

 

AU

 

Pending

 

 

 

 

099VCA

 

UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME

 

CA

 

Pending

 

 

 

 

099VEP

 

UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME

 

EP

 

Pending

 

 

 

 

099VJP

 

UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME

 

JP

 

Pending

 

 

 

 

099VJPD1

 

UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME

 

JP

 

Pending

 

 

 

 

100A

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

US

 

Issued

 

6450984

 

9/17/02

100C1

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

US

 

Issued

 

6626858

 

9/30/03

 

B- 4



 

KMOB
Ref No.
GLAUKO

 

Title of Invention

 

Country

 

Status

 

Patent No.

 

Issued

100C1C1

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

US

 

Issued

 

6827699

 

12/7/04

100C1C2

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

US

 

Issued

 

6827700

 

12/7/04

100CC1C

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

US

 

Issued

 

7850637

 

12/14/10

100CC1C2

 

SHUNT DEVICE AND METHOD FOR TREATING OCULAR DISORDERS

 

US

 

Issued

 

8388568

 

03/05/13

100CC1CD

 

SHUNT DEVICE AND METHOD FOR TREATING OCULAR DISORDERS

 

US

 

Issued

 

8771217

 

7/8/14

100CC2C

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

US

 

Issued

 

8152752

 

04/10/12

100C7

 

SHUNT DEVICE AND METHOD FOR TREATING OCULAR DISORDERS

 

US

 

Pending

 

 

 

 

100CPC1

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

US

 

Issued

 

7220238

 

5/22/07

113VCA

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

CA

 

Issued

 

2368354

 

2/17/09

113VEP

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

DE, FR, GB

 

Issued

 

1173124

 

4/27/05

113VEPD4

 

TRABECULOTOMY DEVICE AND METHOD FOR TREATING GLAUCOMA

 

EP

 

Pending

 

 

 

 

113VJP

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

JP

 

Issued

 

3703721

 

7/29/05

113VR1JP

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

JP

 

Issued

 

4688444

 

2/25/11

113VRCA

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

CA

 

Issued

 

2648346

 

12/4/2012

113VREP

 

SHUNT DEVICE FOR TREATING GLAUCOMA

 

DE, FR, GB

 

Issued

 

1477146

 

8/26/09

113VREP2

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

EP

 

Pending

 

 

 

 

113VREP3

 

SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

DE, FR, GB

 

Issued

 

2116215

 

02/01/12

 

B- 5



 

KMOB
Ref No.
GLAUKO

 

Title of Invention

 

Country

 

Status

 

Patent No.

 

Issued

113VRJPD

 

SHUNT DEVICE FOR TREATING GLAUCOMA

 

JP

 

Issued

 

5323011

 

7/26/2013

119A

 

STENT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

US

 

Issued

 

6464724

 

10/15/02

119C1

 

STENT DEVICE AND METHOD FOR TREATING GLAUCOMA

 

US

 

Issued

 

6783544

 

8/31/04

11CP1C1

 

DEVICES AND METHODS FOR TREATMENT OF OCULAR DISORDERS

 

US

 

Issued

 

7879001

 

02/01/11

11CP1C2

 

DEVICES AND METHODS FOR TREATMENT OF OCULAR DISORDERS

 

US

 

Pending

 

 

 

 

11CP2CP1

 

OCULAR DISORDER TREATMENT IMPLANTS WITH MULTIPLE OPENINGS

 

US

 

Pending

 

 

 

 

11P1C3

 

OCULAR IMPLANT SYSTEMS

 

US

 

Pending

 

 

 

 

11P1C4

 

OCULAR IMPLANT SYSTEMS

 

US

 

Pending

 

 

 

 

11CP3DV1

 

DRUG ELUTING OCULAR IMPLANT WITH ANCHOR AND METHODS THEREOF

 

US

 

Issued

 

8118768

 

2/21/12

11P3D1C1

 

OCULAR SYSTEM WITH ANCHORING IMPLANT AND THERAPEUTIC AGENT

 

US

 

Pending

 

 

 

 

140A

 

SYSTEM AND METHOD FOR DELIVERING MULTIPLE OCULAR IMPLANTS

 

US

 

Pending

 

 

 

 

140CA

 

SYSTEM FOR DELIVERING MULTIPLE OCULAR IMPLANTS

 

CA

 

Pending

 

 

 

 

140EP

 

SYSTEM FOR DELIVERING MULTIPLE OCULAR IMPLANTS

 

EP

 

Pending

 

 

 

 

140JP

 

SYSTEM FOR DELIVERING MULTIPLE OCULAR IMPLANTS

 

JP

 

Pending

 

 

 

 

140NP

 

SYSTEM FOR DELIVERING MULTIPLE OCULAR IMPLANTS

 

NP

 

Pending

 

 

 

 

155A

 

GONIOSCOPE FOR IMPROVED VIEWING

 

US

 

Issued

 

8070290

 

12/06/11

 

B- 6



 

KMOB
Ref No.
GLAUKO

 

Title of Invention

 

Country

 

Status

 

Patent No.

 

Issued

157DA

 

GONIOSCOPIC SYSTEM INCLUDING AN OPTICAL ELEMENT ATTACHMENT

 

US

 

Issued

 

D645489

 

9/20/11

171DA

 

GONIOSCOPIC SYSTEM INCLUDING AN OPTICAL ELEMENT ATTACHMENT

 

US

 

Issued

 

D645490

 

9/20/11

179A

 

SYSTEMS AND METHODS FOR DELIVERING AN OCULAR IMPLANT TO THE SUPRACHOROIDAL SPACE WITHIN AN EYE

 

US

 

Pending

 

 

 

 

179WO

 

SYSTEMS AND METHODS FOR DELIVERING AN OCULAR IMPLANT TO THE SUPRACHOROIDAL SPACE WITHIN AN EYE

 

WO

 

Pending

 

 

 

 

196A

 

GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT

 

US

 

Pending

 

 

 

 

201PR

 

APPARATUS AND METHOD FOR CONTROLLING PLACEMENT OF INTRAOCULAR IMPLANTS

 

US

 

Pending

 

 

 

 

205PR

 

GONIOSCOPIC DEVICES

 

US

 

Pending

 

 

 

 

207PR

 

STABLE THERAPEUTIC DRUG COMPOSITIONS AND IMPLANTS FOR DELIVERY OF SAME

 

US

 

Pending

 

 

 

 

209PR

 

IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME

 

US

 

Pending

 

 

 

 

210PR

 

PUNCTAL IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME

 

US

 

Pending

 

 

 

 

212A

 

ANTERIOR CHAMBER DRUG-ELUTING OCULAR IMPLANT

 

US

 

Pending

 

 

 

 

213WO

 

OCULAR IMPLANTS CONFIGURED TO STORE AND RELEASE STABLE DRUG FORMULATIONS

 

WO

 

Pending

 

 

 

 

214A

 

IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME

 

US

 

Pending

 

 

 

 

214WO

 

IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME

 

WO

 

Pending

 

 

 

 

1C4C11

 

OCULAR IMPLANT WITH ANCHOR AND METHODS THEREOF

 

US

 

Issued

 

8801648

 

8/2/14

1C4C12

 

METHOD OF DELIVERING AN IMPLANT FOR TREATING AN OCULAR DISORDER

 

US

 

Issued

 

8333742

 

12/18/12

1C4C13

 

SYSTEM AND METHOD FOR TREATING AN OCULAR DISORDER

 

US

 

Pending

 

 

 

 

1C4C2

 

METHOD OF DELIVERING AN IMPLANT FOR TREATING AN OCULAR DISORDER

 

US

 

Issued

 

7867205

 

01/11/11

1C2C3DV1

 

IMPLANT DELIVERY DEVICE AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS

 

US

 

Isued

 

8808219

 

8/19/14

 

B- 7



 

EXHIBIT C — GLAUKOS GROUP 2 LICENSED PATENTS

 

(Status as of June 30, 2015)

 

KMOB
Ref. No.
GLAUKO3.

 

Title of Invention

 

Status

 

Patent
No

 

Issued:

001D1

 

OCULAR IMPLANT WITH THERAPEUTIC AGENT AND METHODS THEREOF

 

Issued

 

8814820

 

8/26/14

1C2C3

 

OCULAR IMPLANT WITH ANCHOR AND THERAPEUTIC AGENT

 

Issued

 

8273050

 

09/25/12

005A

 

BIFURCATABLE TRABECULAR SHUNT FOR GLAUCOMA TREATMENT

 

Issued

 

6666841

 

12/23/03

005C1

 

IMPLANT WITH PRESSURE SENSOR FOR GLAUCOMA TREATMENT

 

Issued

 

6981958

 

1/3/06

020C1

 

FLUID INFUSION METHODS FOR OCULAR DISORDER TREATMENT

 

Issued

 

8617094

 

12/31/13

020C2

 

FLUID INFUSION METHODS FOR OCULAR DISORDER TREATMENT

 

Pending

 

 

 

 

022C2

 

COMBINED TREATMENT FOR CATARACT AND GLAUCOMA TREATMENT

 

Issued

 

8882781

 

11/11/14

022C3

 

COMBINED TREATMENT FOR CATARACT AND GLAUCOMA TREATMENT

 

Pending

 

 

 

 

 


Exhibit 10.2

 

AMENDED AND RESTATED TRANSITION SERVICES AGREEMENT

 

This Amended and Restated Transition Services Agreement (this “Agreement” ) is dated as of June 30, 2015 (the “Effective Date” ) by and between Glaukos Corporation, a Delaware corporation ( “Glaukos” ), and DOSE Medical Corporation, a Delaware corporation (“DOSE” ), with reference to the following facts:

 

A.            Glaukos and DOSE are parties to that certain Transition Services Agreement, dated as of March 30, 2010, as amended by those certain letter agreements dated March 31, 2011, March 31, 2012, July 19, 2012, and March 6, 2015 (collectively, the “ Original Agreement ”) pursuant to which Glaukos provides certain services to DOSE.

 

B.            Glaukos and DOSE now wish to amend the Original Agreement as set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Original Agreement is hereby amended and restated to read, and the parties hereto agree, as follows:

 

1.              Provision of Services.

 

1.1          Services Provided .   During the Term, Glaukos hereby agrees to provide to DOSE the services specified on Exhibit A attached hereto (the Services” ), at such times as the parties may mutually agree upon.

 

1.2          Additional Services .   From time to time, DOSE may find it desirable to request, in addition to the Services set forth on Exhibit A , that certain other services be made available by Glaukos (hereinafter referred to as the Other Services” ).  Glaukos shall, in good faith, discuss such request and negotiate in good faith the terms of providing such Other Services including without limitation any increase in the amount of the monthly Fee payable by DOSE pursuant to Section 2.  The provision, if at all, of any Other Services shall be on the terms and conditions agreed upon in writing between Glaukos and DOSE.  Exhibit A shall be amended from time to time to include any Other Services (and the terms and conditions on which they will be provided) agreed to in writing by DOSE and Glaukos.  For the sake of clarity, any such Other Services agreed to and included on Exhibit A , as amended, shall constitute “Services” hereunder.

 

1.3          Rent Payable Under Sublease .  Glaukos and DOSE are parties to that certain Sublease, dated October 15, 2012, pursuant to which Glaukos sublets to DOSE a portion of the property leased by Glaukos and commonly known as 26051 Merit Circle, Suites 103, 104 and 105, Laguna Hills, California (the “ Sublease ”).  Glaukos and DOSE anticipate that following the date hereof, DOSE will only be using a small portion of the space sublet to DOSE pursuant to the Sublease (the “ DOSE Space ”) and Glaukos and DOSE therefore agree that until such time as DOSE begins to use more of the DOSE Space, DOSE will pay to Glaukos rent in the amount of $1,500 per month, rather than the Rent (as defined in the Sublease) provided for in the Sublease.  At such time, if any, as DOSE elects to use more of the DOSE Space, Glaukos and DOSE shall discuss and negotiate in good faith the amount of rent that will be paid by DOSE based upon the amount of the DOSE Space to be used by DOSE.  The agreement of the parties set forth in this Section 1.3 with respect to the amount of rent to be paid by DOSE, shall not affect or modify any of the other terms or provisions of the Sublease, all of which shall remain in full-force and effect.

 



 

1.4          Cancellation .   DOSE may cancel any Service that it is receiving from Glaukos by providing at least ten (10) days prior Notice to Glaukos of its decision to cancel such Service.  Upon any such cancellation, the parties shall negotiate in good faith whether to reduce the amount of the monthly Fee payable by DOSE pursuant to Section 2 in light of such cancelled Services.

 

2.              Fee.  In consideration of the Services, DOSE shall pay to Glaukos a monthly fee of $4,500.00 no later than ten (10) days after the end of each month in which Glaukos provided any Services under this Agreement.

 

3.              Term and Termination.   The term of this Agreement shall be for the period commencing on the Effective Date and continuing through and including June 30, 2018 (the “Term” ); provided, however, that this Agreement may be earlier terminated (a) by DOSE upon not less than sixty (60) days’ prior written notice to Glaukos, (b) by Glaukos upon not less than one hundred eighty (180) days’ prior written notice to DOSE or (c) by mutual agreement of Glaukos and DOSE.  Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination.

 

4.              Direction of Employees; No Agency.  Notwithstanding anything herein to the contrary, Glaukos’ employees providing Services hereunder shall at all times be and remain employees of Glaukos in their performance of Services.  Glaukos shall be responsible for directing and supervising the activities of such employees in their performance of the Services, subject to the directions of DOSE to Glaukos which such directions to be consistent with the terms of this Agreement.  Glaukos shall be solely responsible for the payment of all wages, bonuses, commissions, benefits and any other direct or indirect compensation for their personnel, including those personnel involved in the delivery of the Services, as well as be responsible for their insurance costs and expenses.  This Agreement shall not create a joint venture, partnership, employment, or agency relationship between Glaukos and DOSE, nor shall any party hereto (and its respective affiliates) have the authority to bind any other party hereto in any respect, except as otherwise provided herein.  In its provisions of the Services hereunder, Glaukos shall act under this Agreement solely as an independent contractor and not as an agent of DOSE.

 

5.              No Representations or Warranties.  All Services will be provided by Glaukos “as is” with no warranties or representations of any kind whatsoever, express or implied, whether arising under law, equity, custom, usage or otherwise, including without limitation any implied warranties of merchantability and any warranty that the Services are fit for any particular purpose.

 

6.              Indemnification.  DOSE hereby agrees to indemnify and hold Glaukos and its directors, officers, employees, Affiliates, stockholders, agents and assigns harmless from and against any and all claims, losses, damages, liabilities, deficiencies, obligations or out-of-pocket expenses and costs and expenses of investigation, arising out of or resulting from Glaukos’ performance or nonperformance of the Services hereunder except for gross negligence or willful misconduct of Glaukos.

 

2



 

7.              Confidentiality.

 

7.1          Use of Confidential Information .   From time to time prior to the commencement of and during the Term, each party hereto has disclosed or may disclose its confidential information (e.g., information regarding a disclosing party’s business and operations, research and development activities, pre-clinical and clinical data, regulatory strategies and submissions, products, customers, employees, financial results, contractual relationships, etc.) to the other party.  In addition each party may, from time to time during the Term, obtain or have access to the other party’s confidential information.  As used herein, the term “confidential information” does not include information that (i) is in or comes into the public domain through no fault of the receiving party or any of its affiliates or their representatives, or (ii) is lawfully acquired without confidentiality obligations to the disclosing party from sources having the right to make such disclosure or (iii) was developed independently by the receiving party without use of any confidential information of the disclosing party.  Each party shall maintain (and cause its affiliates and subcontractors to maintain) the confidentiality of the other party’s confidential information and not to use or disclose such confidential information except as required to perform its obligations in accordance with this Agreement or as permitted hereby or by the disclosing party in writing.  If compelled to disclose any confidential information by judicial or administrative process or by requirement of law, the receiving party shall promptly notify the disclosing party in writing and, if legal protection is not obtained, may disclose only that portion of such information that is legally required to be disclosed as advised by counsel; provided that the receiving party shall exercise commercially reasonable efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.  Because of the unique nature of the confidential information, the parties understand and agree that the disclosing party will suffer irreparable harm in the event that a party which receives such disclosing party’s confidential information fails to comply with any of its obligations hereunder and that monetary damages will be inadequate to compensate disclosing party for such breach.  Accordingly, each party agrees that the disclosing party shall, in addition to any other remedies available to it at law or in equity, be entitled to seek injunctive relief to enforce the terms hereof.

 

7.2          Return of Confidential Information .   Upon termination of this Agreement, unless a party has a continuing right to use such confidential information pursuant to a license granted hereunder, upon request of the other party, each of the parties hereto agrees to return to the other all such confidential information of the other, or, at its option destroy such confidential information and, thereafter, certify immediately to the disclosing party that all such confidential information has been returned or destroyed.

 

3



 

8.              Ownership of New Technology.

 

8.1  New Technology .

 

(a)           Except as provided in Section 8.2 below, any and all (i) inventions (whether or not reduced to practice and whether or not patentable), (ii) works of authorship, (iii) trade secrets, know-how, confidential information (including but not limited to confidential ideas, research and development, technology, discoveries, methods, formulas, compositions, manufacturing processes, designs, specifications, clinical trial protocols, statistical analyses and other regulatory information, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals) and all other proprietary information and data (including but not limited to technical and safety, efficacy and other clinical data) conceived, developed or reduced to practice by Glaukos or DOSE, either jointly or individually, in whole or in part, during the period beginning on July 10, 2014 and ending upon the expiration of the Term (collectively, “New Technology” ) shall be owned by (i) DOSE to the extent such New Technology is within the Dose Field of Use as defined in the Amended and Restated Patent License Agreement dated as of June 30, 2015, between Glaukos and DOSE, as the same may be amended from time to time (the “ Glaukos/DOSE License Agreement ”), and (ii) Glaukos to the extent such New Technology is outside the Dose Field of Use.

 

(b)           Each party shall disclose to the other party any New Technology promptly after it has been conceived, developed or reduced to practice.  For purposes of this Section 8, all determinations of inventorship shall be made in accordance with United States patent law.  For no additional consideration, each party (the “Assignor” ) hereby assigns to the applicable other party (the “Assignee” ) all of the Assignor’s right, title and interest, worldwide, in and to any New Technology (including without limitation all intellectual property rights associated therewith and all copies and tangible embodiments thereof, in whatever form or medium) consistent with the ownership allocation described above so that sole and exclusive ownership therein resides in DOSE to the extent such New Technology is within the Dose Field of Use and in Glaukos to the extent such New Technology is outside the Dose Field of Use.  Each applicable Assignor shall, at the applicable Assignee’s request and expense, execute documents and perform such acts as such Assignee may deem necessary, to confirm in such Assignee, all right, title and interest throughout the world, in and to any New Technology consistent with the ownership allocation set forth herein (including all patents, trademarks copyrights and other applicable statutory protections thereon), and to enable and assist Assignee in procuring, maintaining, enforcing and defending patents, trademarks, copyrights and other statutory protections throughout the world in and to any such New Technology.  Each party shall cause each of its employees, contractors and consultants to execute and deliver an agreement assigning all of their respective right, title and interest in and to any New Technology consistent with the above ownership allocation so that sole and exclusive ownership therein resides in DOSE to the extent such New Technology is within the Dose Field of Use and in Glaukos to the extent such New Technology is outside the Dose Field of Use.

 

8.2          Exceptions .  Notwithstanding Section 8.1:

 

(a)           By way of clarification and for the avoidance of doubt, the term “New Technology” shall not include any invention that is the subject of any patent or patent application included within the definitions of “Dose Licensed Patents”, “Glaukos Group 1 Licensed Patents” or “Glaukos Group 2 Licensed Patents” as such terms are defined in the Glaukos/Dose License Agreement or within the definition of “Assets” as such term is defined in the Asset Purchase Agreement, dated as of July 10, 2014, between Glaukos and DOSE.

 

4



 

(b)           Any New Technology to the extent it relates to (i) a delivery device for a Glaukos product (irrespective of whether such delivery device can also be used or modified to deliver a DOSE product); (ii) a visualization device or method (e.g., for targeted placement of an implant); (iii) an introducer or corneal penetration device (whether apart from or part of a delivery device); or (iv) a device or method for accessing in an ab interno manner the suprachoroidal space or the supraciliary space (for example, an integrated spatula or a method of “teasing of ciliary”) shall be owned by the party conceiving, developing or reducing to practice such New Technology, provided that, the party owning such New Technology hereby grants to the other parties a non-exclusive, irrevocable, perpetual, fully paid-up, worldwide license, with the right to sublicense, to use such New Technology (including without limitation the right to copy and create derivative works) to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products, and to practice any and all inventions, within the Glaukos Field of Use (as defined in the Glaukos/DOSE License Agreement) if such other party is Glaukos and within the Dose Field of Use if such other party is DOSE.

 

9.              Miscellaneous.

 

9.1          Binding Effect .  This Agreement will be binding upon, and inure to the benefit of, the parties and their respective successors and assigns.

 

9.2          Captions .  Section titles, captions and headings contained herein are inserted as a matter of convenience and are for reference only and they do not define, limit, extend or describe the scope of this Agreement or any provision hereof.

 

9.3          Notices .  All notices, requests, demands, claims and other communications hereunder ( “Notices” ) shall be in writing.  Any Notice hereunder shall be deemed duly given (i) upon receipt if delivered in person; (ii) on the date delivered by Federal Express, UPS, DHL or similar international courier service as established by the sender by evidence obtained from the courier; (iii) upon transmission by facsimile, provided an electronic acknowledgement of receipt is generated; or (iv) on the fifth day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid; in each case addressed to the intended recipient as set forth below (or to such other address or facsimile number as the intended recipient may request by way of an appropriate Notice given in accordance with this Section):

 

If to DOSE:

If to Glaukos:

 

 

DOSE Medical Corporation

Glaukos Corporation

26051 Merit Circle, Suite 105

26051 Merit Circle, Suite 103

Laguna Hills, CA 92653

Laguna Hills, CA 92653

Facsimile No.: 949-367-9984

Facsimile No.: 949-367-9984

 

9.4          Waiver .  The waiver by either party of any breach by the other party of any of the representations, warranties, promises and/or covenants contained herein shall not prevent the subsequent enforcement of any such representation, warranty, promise and/or covenant as to any aspect which has not been waived, nor shall it be deemed a waiver of any subsequent breach thereof.  No waiver of any breach or violation hereof shall be implied from forbearance or failure by a party to take action thereon.

 

5



 

9.5          Assignment .  During the Term, neither party shall assign this Agreement or any right, interest or benefit under this Agreement, nor delegate any of its duties or obligations hereunder, without the prior written consent of the other party.  For the avoidance of doubt, after the Term, each of Glaukos and DOSE shall have the right to assign in whole or in part its rights, obligations and licenses under this Agreement.  Except as permitted by the foregoing, any attempted assignment or delegation shall be null, void, and of no effect.  Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the successors and assigns of each of the parties.

 

9.6          Entire Agreement .  This Agreement, including the exhibits attached hereto, constitutes the entire agreement between the parties hereto regarding the subject matter hereof and no terms, conditions or provisions other than those expressly contained herein shall be deemed to be part of this Agreement.  This Agreement supersedes any prior agreements (oral or written) between the parties. The exhibits identified in this Agreement are incorporated herein by reference and made a part hereof.  Without limiting the foregoing, in the event of any conflict between Section 10 of the Employee Leasing Agreement dated March 30, 2010, between Glaukos and DOSE, as amended by those certain letter agreements dated March 31, 2011, March 31, 2012, July 19, 2012 and March 6, 2015 (the “Employee Leasing Agreement”) and Section 8 of this Agreement, then notwithstanding anything in the Employee Leasing Agreement to the contrary, Section 8 of this Agreement shall control.

 

9.7          Amendments .  Neither this Agreement nor any of the terms or conditions hereof may be waived, amended or modified except by means of a written instrument duly executed by both parties.

 

9.8          Attorneys’ Fees .  In any action to enforce this Agreement, the prevailing party shall be awarded all court costs and reasonable attorneys’ fees incurred, including such costs and attorneys’ fees incurred in enforcing and collecting any judgment.

 

9.9          Cumulative Remedies .  The remedies set forth in this Agreement are cumulative and shall be in addition to any and all other remedies available at law or in equity.

 

9.10        Further Assurances .  The parties, without further consideration of any kind, shall each execute and deliver, or cause to be executed and delivered, such other instruments, and take, or cause to be taken, such other action, as shall reasonably be requested by the other party hereto to more effectively carry out the terms and provisions of this Agreement.

 

9.11        Severability .  Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction.

 

9.12        Survival .   The provisions of Sections 4, 6, 7, 8 and 9 shall survive the termination of this Agreement.

 

6



 

9.13        Counterparts .   This Agreement may be executed in any number of counterparts which together shall constitute one and the same instrument.  Delivery of an executed counterpart of a signature page by facsimile shall be effective as delivery of a manually executed counterpart.

 

9.14        Governing Law .  This Agreement shall be governed by and construed under the internal laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California, without reference to principles of conflict of laws or choice of laws.

 

[SIGNATURE PAGE FOLLOWS]

 

7



 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their authorized representatives as of the day and year first above written.

 

 

GLAUKOS CORPORATION

 

 

 

 

 

By:

/s/ THOMAS W. BURNS

 

 

Thomas W. Burns

 

Its:

President & CEO

 

 

 

DOSE MEDICAL CORPORATION

 

 

 

 

 

By:

/s/ RICHARD L. HARRISON

 

 

Richard L. Harrison

 

Its:

Chief Financial Officer

 

8



 

EXHIBIT A

 

Services

 

1.             Services

·                   Accounting, administrative, legal, human resources and financial services

·                   General ledger accounting services, including but not limited to:

·                   bookkeeping

·                   month-end closing

·                   Cash management

·                   Accounts payable management and bill paying

·                   Payroll and benefits administrative services

 

2.             IT Support

 

3.             Limited Engineering Support